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Background and Purpose: Health care workers caring for adults in the Supportive 
Living setting (SLS) are at risk for exposure to hazardous medications. To control 
workers’ exposure, Alberta Health Services developed the Hazardous Medication 
Personal Protective Equipment Guide and List (the Guide). The overall goal of this 
practicum was to conduct a critical appraisal of that Guide with recommendations for 
future implementation and evaluation. Methods: Three methods of data collection were 
used to inform the critical appraisal: a comprehensive review of the literature, 
consultations with key informants, and an environmental scan of hazardous medication 
management resources. Results: A critical appraisal of the Guide using the Appraisal of 
Guidelines for Research and Evaluation (AGREE II) Instrument showed that it was a 
high quality clinical practice guideline. Conclusion: The Guide is recommended for use 
in the supportive living setting, with minor modifications in the Applicability and 
Editorial Independence domains.  
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Health care workers (HCW) in the Supportive Living setting (SLS) are at risk for 
occupational exposure to hazardous medications, which can result in adverse health 
effects. As outlined in the Occupational Health and Safety (OHS) Code, an employer is 
responsible to assess a worksite for existing and potential hazards and take measures to 
eliminate or control said hazards (Government of Alberta, 2018). To control workers’ 
exposure to hazardous medications, and enhance worker and patient safety, Alberta 
Health Services (AHS) developed the Hazardous Medication Personal Protective 
Equipment (PPE) Guide and List, henceforth referred to as the Guide (AHS, 2018a). The 
Guide was created by a panel of experts and frontline HCWs across the province of 
Alberta and, “is intended to provide guidance to all employees, members of the medical 
and midwifery staffs, students, volunteers, and other persons acting on behalf of AHS 
including contracted service providers as necessary” (AHS, 2018a, p. ii). The Guide 
consists of a list of medications that represent either, a known, potential, or reproductive 
hazard, and the safety measures needed to protect HCWs in performing any task 
involving an exposure to said hazards. This practicum project involved the critical 
appraisal of the Guide including stakeholder reactions to the implementation of the Guide 
at one test site. 
Background 
Prior to the inception of the Guide, HCWs in the SLS referred to the Cytotoxic 
Drug Manual Administration and Handling Guidelines (AHS, 2013) to identify the 
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required safety measures when working with cytotoxic medications. The new Guide 
deviates from the Cytotoxic Drug Manual Administration and Handling Guidelines (the 
Manual) in a number of ways, which will have significant implications for HCWs caring 
for older adults living in the community. While the Manual lists only cytotoxic drugs that 
necessitate control measures when being handled, the new Guide contains an extensive 
list of all hazardous medications, adopted directly from the National Institute for 
Occupational Safety and Health (NIOSH, 2016). The NIOSH list includes cytotoxic 
medications as well as those that are teratogenic, genotoxic, toxic to organs, and those 
that mimic other known hazardous medications (AHS, 2018a). As such, the list of 
medications representing an occupational hazard under the new guide is significantly 
longer and includes common medications such as carbamazepine, estrogen/progesterone 
containing medications, clonazepam, valproic acid, and warfarin. The Guide also contains 
specific recommendations for the use of PPE and the disposal of hazardous medications 
that will require changes to existing practices in the SLS. 
Following a province wide educational roll out of the Guide in January of 2018, a 
number of questions and concerns came forward regarding how this Guide could be 
implemented successfully in the SLS which is a stream of the Continuing Care program 
that partners with contracted service providers to care for adults living in the community. 
Challenges to implementing the new Guide in this setting include the following: (1) 
increased costs associated with providing more PPE and spill kits, (2) communicating 
hazardous medication risk to all HCWs in the SLS, (3) ensuring pharmacies affix the 
correct hazardous medication warning labels to prescriptions, and (4) disposal of bio 
hazardous wastes in the SLS.  
7 
 
In an effort to validate the Guide as an appropriate clinical practice guideline 
(CPG) for the SLS setting, a critical appraisal of the Guide was conducted. This appraisal 
included consultations with key stakeholders to collect essential information about the 
implementation of the Guide in one test site. Findings from this critical appraisal and key 
informant reactions to implementing the Guide at one test site could provide essential 
information to formulate recommendations for the future implementation and evaluation 
of the Guide.  
Goal and Objectives 
 
The overall goal for this practicum was to critically appraise the Hazardous 
Medication Personal Protective Equipment Guide and List (AHS, 2018a) to determine 
whether it was a quality CPG that could be used by HCWs caring for adults in the SLS. 
The key practicum objectives are: 
1. Demonstrate advanced nursing practice competencies through research, 
leadership, clinical, and collaborative activities. 
2. Conduct a comprehensive literature review as it relates to the development and 
evaluation of CPGs for exposure to hazardous medications. 
3. Appraise the quality of the Guide using the Appraisal of Guidelines for Research 
and Evaluation (AGREE) Instrument.  
4. Conduct consultations with key informants to determine reactions to the 
implementation of the Guide at one test site. 
5. Identify the barriers and facilitators for successful implementation of the Guide. 
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6. Apply findings from the critical appraisal to make recommendations for future 
implementation and evaluation of the Guide. 
7. Disseminate the findings of this practicum by participating in knowledge-transfer 
techniques such as presentations. 
Methods 
 
A number of methods were employed to achieve the aforementioned practicum 
objectives. First, a comprehensive review of the literature was completed to examine the 
current literature as it relates to the development and evaluation of CPGs (see Appendix 
A). From this review, the AGREE II was identified as a valid and reliable tool to critically 
appraise the quality of the Guide. Second, consultations were conducted with key 
informants to determine stakeholder reactions to the implementation of the Guide at one 
site (see Appendix B). Third, an environmental scan was conducted to create an 
awareness of available local, provincial, and national resources for handling hazardous 
medications in the SLS (see Appendix C). Finally, a critical appraisal of the Guide was 
completed using the AGREE II Instrument (see Appendix D). 
Summary of Literature Review 
 
A comprehensive review of the literature was conducted to examine the current 
state of evidence as it relates to the critical appraisal of CPGs using the AGREE II 
Instrument (see Appendix A). Questions that guided this literature review included: 1) 
What is the current literature as it relates to the development and evaluation of CPGs? 2) 
Has the AGREE II Instrument been used to evaluate the quality of CPGs for handling 
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hazardous medications? and 3) Is the AGREE II an appropriate instrument to critically 
appraise the Guide? 
 To complete this review, a search of the Cumulative Index of Nursing and Allied 
Health Literature and PubMed databases was conducted using the terms: clinical practice 
guidelines, hazardous medications, AGREE II, occupational health and safety or 
occupational medicine or workplace health and safety or occupational health nursing. A 
thorough review of the content of the AGREE Trust website was also completed. Results 
were limited to articles written in English with a publication date between 2010 and 2018 
as version two of the AGREE Instrument was not released until 2010. Abstracts were 
reviewed for relevancy and any articles that met the exclusion criteria were discarded 
leaving seventeen articles for review. Exclusion criteria included: letters to the editor, 
those inaccessible through library holdings, and those that involved research using 
modified versions of the AGREE II Instrument.  
Of the seventeen articles screened, eight were either research articles or literature 
reviews. Those articles underwent a critical appraisal using the Public Health Agency of 
Canada’s (PHAC, 2014) Critical Appraisal Toolkit. In reading the aforementioned 
articles, the Guideline Implementability for Decision Excellence Model (GUIDE-M) was 
identified as a relevant adjunct to the AGREE II. As such, two articles about the GUIDE-
M were also screened into the review and underwent a critical appraisal. The themes 
gleaned from this comprehensive review of the literature are described in depth in the 
Literature Review Report (see Appendix A) and key findings from the review are 
summarized below.   
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The first key finding from this review was that the Guide (2018a), did meet the 
requirements to be considered a CPG in that it is: 1) intended to aid clinicians in decision-
making and 2) that it is the product of a systematic review of the evidence (Anaya, 
Franco, Merchan-Galvis, Gallardo, & Cosp, 2018). Another important finding from the 
literature review was identifying that the AGREE II was an appropriate tool to appraise 
the quality of CPGs such as the Guide (AGREE Trust, 2017). Two research articles 
demonstrated the validity and reliability of the AGREE II Tool, the use of which to 
appraise CPGs is widely cited in the literature. While no articles were found whereby the 
AGREE II was used to appraise a hazardous medication CPG, there were three articles 
found where the tool was used for other OHS related guidelines.  
Another key finding from the literature review were the limitations of the AGREE 
II Instrument. The most widely cited limitation is the fact that the tool is intended to be 
used to evaluate the methodological quality of CPG development, not the clinical 
appropriateness or validity of the recommendations within it (Anaya et al., 2018; Bragge 
et al., 2014; Brouwers et al., 2010a; Joosen et al., 2015; MacQueen et al., 2017). Other 
limitations of the AGREE II are that it is not intended to appraise the quality of guidance 
documents that address health care organizational issues and it has not been formally 
evaluated as a tool to appraise health technology assessments (AGREE Trust, 2017). 
Additionally, the AGREE II does not provide a means to assess the end user’s adherence 
to a CPG in practice nor evaluate the clinical impact of the guideline (Joosen et al., 2015). 
Finally, the instrument does not provide guidance regarding how the CPG should be 
implemented (Brouwers et al., 2010a; Joosen et al., 2015).  
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An additional key finding from the literature review was the identification of the 
GUIDE-M, a complimentary tool to the AGREE II. The GUIDE-M is a framework of 
intrinsic factors affecting the implementability of CPGs designed to support their 
implementation (AGREE Enterprise, 2018). The GUIDE-M was used as a theoretical 
point of reference to inform the critical appraisal and subsequent recommendations for 
future implementations of the Guide.  
The final key finding from this review was the substantial evidence in the 
literature highlighting inconsistencies in the quality of CPGs, with many failing to meet 
even basic standards (Brouwers et al., 2010a; Brouwers et al., 2010b; Dewa, Trojanowski, 
Joosen & Bonato, 2016; Makarski & Brouwers, 2014). This represents a significant 
problem as a low level of quality limits the potential benefits of CPGs. The benefits of 
high quality CPGs include optimizing patient care, supporting the efficient use of 
resources, promoting a positive attitude among practitioners, and informing policy-, 
system-, and population-related decisions (Anaya et al., 2018; Brouwers, Makarski, 
Kastner, Hayden & Bhattacharyya, 2015). In summary the review of the literature 
revealed that the AGREE II instrument is a reliable and valid tool for critically appraising 
CPGs and although it has not been used to appraise CPGs for handling hazardous 
medications it is an appropriate instrument to guide the critical appraisal of the Guide.  
Summary of Consultations 
 
Consultations were conducted with key informants at one test site to identify the 
current implementation plan for the Guide, identify the key informants’ perception of the 
Guide, examine barriers and facilitators that affect the implementation of the Guide and 
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identify strategies and recommendations to support the successful implementation of the 
Guide. Ten interviews were conducted with key informants using a face-to-face semi-
structured interview. Informants included: an Administrative Manager, a Nursing Team 
Lead, three HCWs, a Case Manager, a Program Manager, a pharmacist from a contracted 
pharmacy, a representative from the Continuing Care Hazardous Medication Committee 
(HAZMEC), and a Continuing Care Senior Workplace Health and Safety Advisor. Data 
was collected until a critical point of data saturation was reached and then underwent 
content analysis. All findings from the consultations are documented in the Consultation 
Report (see Appendix B). Common themes revealed from the content analysis included: 
informants’ perception of the guide (awareness and use), the factors that supported or 
hindered the implementation of the Guide, the current implementation plan, and strategies 
and recommendations to support the successful implementation of the Guide.  
Informants’ perception of the guide. The findings from the consultations 
revealed that all key informants were aware of the existence of the Guide, although the 
platform from which it was accessed varied. Some informants relied on paper copies of 
the Guide while others accessed it electronically from the organization’s website. Some 
informants used the Guide in its entirety while others only referred to sections within it 
(e.g. the waste management posters or the list of hazardous medications). Key informants 
identified the main factors supporting the successful implementation of the Guide 
including: 1) easy to read, 2) the content is self-explanatory; 3) the visual material 
including the posters and pictures enhance the understanding of the content and provide 
quick access to important information; 4) the algorithm summarizing how to use the 
Guide, and 5) the inclusion of contact information for hazardous medication experts 
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within the organization. The main barriers to successful implementation included a lack 
of knowledge about the Guide and lack of resources to implement the recommendations 
(e.g. the cost of more spill kits, purchasing a waste disposal system, etc.).  
Recommendations arising from consultations included the need for HCWs to have 
an orientation to the Guide, the need to identify the costs associated with implementing 
the recommendations, and the need to develop patient and family resources to address 
risk associated with handling hazardous medications. 
Barriers and facilitators to implementation. Factors that hindered 
implementation of the recommendations from the Guide included: 1) the expanded, long, 
comprehensive list of medications and recommendations, 2) the length of the hazardous 
medication list is too inclusive by including commonly prescribed medications such as 
warfarin, 3) a lack of clarity whether common medications on the potential hazard list 
should in fact be handled as a hazardous medication if handled in low doses, e.g. 
warfarin, 4) the list contains medications that were not previously handled as hazardous, 
5) it is a challenge to enforce the recommendations in the SLS, 6) program level 
processes have not been developed, and 7) having to contact an external resource for 
program specific processes could delay implementing the recommendations in the Guide.  
Recommendations from informants to improve the content of the Guide included: 
1) indicate the specific spill kits that are recommended, 2) clarify the precautions required 
for clients and families who are potentially exposed to hazardous medications, and 3) 
provide more direction regarding the difference between PPE to protect a worker from 
hazardous medication exposure and those required for infectious disease exposure. 
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Current implementation plan. Key informants identified four primary 
implementation strategies that were currently in use at the test site. One key strategy 
identified was the initial and ongoing education and support provided to the HCWs, 
clients and families of clients taking a known hazardous medication. Another strategy 
used to implement the Guide was the collaboration with community pharmacies to set up 
a process for identifying, preparing, and labeling hazardous medications. The third 
implementation strategy was the development of site-specific processes for managing 
hazardous medications. The final strategy was to ensure the equipment required for the 
management of hazardous medications was readily available to HCWs (e.g. PPE, waste 
disposal systems).  
Implementation strategies and recommendations. Key informants made a 
number of specific recommendations to support the successful implementation of the 
Guide including providing an education session on the contents of the Guide, a 
demonstration of the donning and doffing of PPE and a demonstration of how to draw up, 
administer, and dispose of a hazardous medication. Key informants also recommended 
developing site-specific processes for hazardous medication management and assigning a 
clinical lead or resource person to implement the recommendations from the Guide. 
Continued collaboration with all pharmacy providers was also recommended to ensure 
processes are in place to identify and label hazardous medications.  
Key informants also identified the need to evaluate ongoing compliance to the 
Guide by conducting regular audits to ensure: hazardous medications are correctly 
identified and labeled by pharmacy, hazardous medications are identified and 
communicated as being hazardous amongst the facility HCWs, the correct PPE is being 
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used, waste management requirements are being followed, and site specific hazardous 
medication management processes are followed. Key informant recommendations are 
discussed in detail in Appendix B.  
Summary of Environmental Scan 
 
An environmental scan was completed to identify local, provincial, and national 
CPGs for HCWs handling hazardous medications in the SLS. The data for this 
environmental scan was collected in three ways. First, a Google search using the terms 
“hazardous medications” and “Canada” was conducted. Second, the following 
websites/online platforms were reviewed to identify relevant resources: 1) Supportive 
Living Share Point, 2) Alberta Health Services Insite, 3) the Government of Alberta 
Occupational Health Services Online Resource Portal, 4) the Canadian Centre for 
Occupational Health and Safety (CCOHS) Website, and 5) the Canadian Clinical Practice 
Guideline Infobase. Finally, a question about the availability of hazardous medication 
resources (at the local, provincial, and national level) had been included in the 
consultations with the Continuing Care Workplace Health and Safety Advisor and 
Continuing Care HAZMEC Member.  
Nine resources were found in conducting this scan, four of which met the criteria 
to be considered a CPG. These CPGs include: the AHS Edmonton Zone Cytotoxic Drug 
Manual Administration and Handling Guidelines (2013), Safe Handling of Hazardous 
Drugs from the British Columbia Cancer Agency (2017), Safe Handling of Hazardous 
Drugs in Healthcare authored by the Ontario Public Services Health and Safety 
Association (2017), and NIOSH List of Antineoplastic and Other Hazardous Drugs in 
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Healthcare Settings (2016). Also, three supporting documents for the Guide were 
identified: the Hazardous Medication Personal Protective Equipment Frequently Asked 
Questions (AHS, 2018b), the Hazardous Medication Personal Protective Equipment 
Guide and List Tip Sheet (AHS, 2018c), and the Handling Human Wastes of Patients 
Receiving Known Hazard Medications Frequently Asked Questions (AHS, 2018d). A 
complete report of the findings from this environmental scan can be found in the 
Environmental Scan Report (see Appendix C). The content of these resources were 
reviewed and taken into consideration during the critical appraisal of the Guide. 
Summary of Critical Appraisal of the Guide 
 
 The overall goal for this practicum was to critically appraise the Hazardous 
Medication Personal Protective Equipment Guide and List (AHS, 2018a) to determine 
whether it was a quality CPG that could be used by HCWs caring for adults in the SLS.  
Critical appraisal process. The critical appraisal process began with obtaining a 
copy of the Guide and carefully reading the entire document to become familiar with the 
contents. The content of the Guide was then compared to the resources found in the 
environmental scan to ensure the Guide contained the most recent evidence for practice in 
Canada. All of the supporting documents used in the development of the Guide were 
collected and reviewed as a part of the materials considered in the critical appraisal 
process. A member of the guideline development group was also consulted to obtain 
information about the development process of the Guide. All of this information was then 
used to complete the critical appraisal of the Guide using the AGREE II Instrument.  
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AGREE II critical appraisal. The AGREE II Online Guideline Appraisal Tool 
was used to conduct the appraisal and create a summary report (see Appendix D). 
Overall, the quality of the Guide was high and it is recommended HCWs use the Guide to 
help to control their exposure to hazardous medications, and enhance worker and patient 
safety. However, the low scores in two domains warrant consideration for future versions 
of the Guide. 
Applicability and Editorial Independence domains. The Guide received high 
quality scores for all domains except for the Applicability domain, which received a 
medium quality score of 67%, and the Editorial Independence domain, which received a 
low quality score of 21%. A key reason for the lower score in the Applicability domain 
was a failure to address the resource implications of implementing the recommendations 
within the Guide, specifically the costs of the PPE, spill kits, waste management 
equipment, and waste management processing as well as who is responsible for those 
costs. Another reason for the lower Applicability score was that the Guide does not 
provide any monitoring or auditing criteria to evaluate implementation. The Editorial 
Independence domain received the lowest quality rating of 21%, well below the pre-set 
threshold. The low rating for this domain is due to the fact that there is no explicit 
statement acknowledging that the views or interests of the funding body have not 
influenced the content of the Guide, nor is there any conflict of interest statement on 
behalf of the guideline development group members.     
Recommendations arising from the critical appraisal to improve the quality of the 
Guide include the following:  
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1. Add a section with the names, disciplines, relevant expertise, institution, 
geographic location, and the role of each member who was involved in the 
development of the Guide.  
2. Describe the development process including the methodology used to 
conduct the external review, the strategy used to search for and select the 
evidence, and a description of the strengths and limitations of the 
evidence.  
3. Develop a procedure for updating the contents of the Guide.  
4. Identify the costs of PPE, spill kits, waste management equipment, and 
waste management processing as well as who is responsible for those 
costs.  
5. Develop monitoring and/or auditing criteria to conduct an evaluation of the 
implementation of the Guide (e.g. hazardous medications are correctly 
identified and labeled by pharmacy, hazardous medications are identified 
and communicated as being hazardous amongst the facility HCWs, the 
correct PPE is being used, waste management requirements are being 
followed, and site specific hazardous medication management processes 
are followed).  
6. Include a statement explicitly stating the role of the funding body in the 
development of the Guide.  
7. Include a statement explicitly declaring the presence or absence of any 




Summary of recommendations for the guide. In summary, the following 
recommendations have been developed based on the literature review, key informant 
consultations, an environmental scan and the critical appraisal of the Guide using the 
AGREE II and are in addition to the recommendations arising from the critical appraisal: 
1. Develop site-specific processes to guide HCWs caring for clients receiving 
hazardous medications in the SLS.  
2. Provide an orientation to- and ongoing education sessions on the Guide.  
3. Develop an educational resource for clients and families based on the Guide (e.g. 
pamphlet).  
4. Print and distribute the “point-of-care” visual aids that accompany the Guide (e.g. 
PPE poster).  
5. Collaborate with pharmacy providers to ensure consistent processes are in place to 
identify and label all hazardous medications. 
6. Ensure the required PPE and waste disposal equipment, as outlined in the Guide, 
is available to all HCWs at point of care. 
Advanced Nursing Practice Competencies 
 
 In completing this critical appraisal of a CPG, I have demonstrated a number of 
advanced nursing practice competencies including: health system optimization, education, 
research, leadership, and consultation and collaboration (Canadian Nurses Association 
[CNA], 2019). The following is a discussion of examples of behaviours that demonstrate 
how I achieved those advanced practice competencies. 
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Health System Optimization  
 
 Health system optimization competencies involve making “contributions to the 
effective functioning of health systems through advocacy, promoting innovative client 
care and facilitating equitable, client-centered health care (CNA, 2019, p. 30).” The 
critical appraisal completed for this practicum yielded a number of recommendations that 
constitute a strategic plan to support the implementation of the Guide. By enhancing the 
implementability of the Guide, the objectives of the CPG, to control workers’ exposure to 
hazardous medications and enhance worker and patient safety, can be realized. This will 
ultimately enhance care provision in the SL program, which will support the functioning 
of the healthcare system.  
Education 
 
 Education competencies involve a commitment to the professional growth and 
development of HCWs as well as clients’/families’ learning as it relates to health and 
wellness (CNA, 2019). Education competencies were demonstrated by identifying the 
learning needs of the HCWs who use the Guide. Through consultations with the test site 
HCWs, a number of learning needs with respect to the Guide were identified including: 
the use of the Guide, the correct donning and doffing of PPE, the site specific process for 
managing hazardous medications, and the correct way to draw up, administer, and 
dispose of an injectable hazardous medication. In order to support the professional growth 
of HCWs who use the Guide, a recommendation to provide education targeted at meeting 
the aforementioned learning needs was formulated. Furthermore, a need was identified to 
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provide education to clients taking hazardous medications, and their families, in order to 
protect them from unintended exposure to hazardous medications and ease their anxieties 
about the PPE being used during the provision of care.    
Research  
 
Research competencies involve the generation, synthesis, critique, and application 
of research evidence (CNA, 2019). Although the focus of this project was on evaluation 
not research, a number of these competencies were achieved in completing the critical 
appraisal of the Guide. First, findings from a comprehensive review of the literature were 
critiqued, interpreted, and synthesized into the final integrative review. This involved a 
critical appraisal of the literature, including the development of research summary tables. 
Furthermore, the results of the literature review were applied to inform the critical 
appraisal of the Guide. This included the decision to use the AGREE II Instrument for the 
critical appraisal, the development of questions for the semi-structured interviews, and the 
identification of relevant CPGs applicable through the environmental scan.  
Second, data was collected by means of semi-structured interviews with key 
informants followed by content analysis to identify common themes. These findings were 
then applied, along with those identified in completing the critical appraisal of the Guide, 
to develop recommendations for the future implementation and evaluation of the Guide. 
Finally, this practicum project required me to act as a knowledge broker whereby I will 
share evidence informed recommendations with relevant stakeholders for the purpose of 
benefiting HCWs, client care, and the healthcare system as a whole. This evidence will be 
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further shared using multiple means including submitting an article for publication to the 




Leadership competencies require the advanced practice nurse to be “agents of 
change, consistently seeking effective new ways to practice, improve care and promote 
advanced practice nursing (CNA, 2019, p. 33).” Leadership was demonstrated in 
completing this project first, by identifying the implementation of the Guide in the SLS as 
a complex problem cofounded by numerous barriers. Second, by completing a critical 
appraisal of the Guide to identify effective and innovative ways to address the challenges 
associated with implementing the Guide. Developing recommendations to support the 
implementation and ongoing evaluation of the Guide, demonstrates the leadership 
competency of being an agent of change. 
Consultation and Collaboration  
 
 Consultation and collaboration advanced nursing practice competencies involve 
effective communication and collaboration with colleagues across sectors and at the 
organizational, provincial, national, and international levels (CNA, 2019). Collaboration 
with relevant stakeholders occurred throughout the project at the organizational and 
provincial level. This included collaborating with key informants to identify and define 
the need for the critical appraisal of the Guide. Consultation competencies were also 
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demonstrated in completing this project by conducting formal consultations with key 
informants, the findings from which were used to inform the critical appraisal. 
Next Steps for Implementation and Evaluation of the Guide 
 
 With the critical appraisal complete and associated recommendations developed, 
the next step is to disseminate the findings of this practicum project in an effort to 
promote the successful implementation of the Guide in the future. A copy of this report 
will be provided to the contact person for this practicum and key informants as requested. 
The author will search for opportunities to present the findings of the critical appraisal at 
local or provincial education sessions. One possible venue for a presentation on the Guide 
would be through the Mentor Moment Session; an online education forum delivered 
through Skype. The next steps for the implementation of the Guide would be to develop a 
future plan for orientation and ongoing education sessions for HCWs throughout the 
organization.  
Recommendations from the critical appraisal also indicate the need for an 
evaluation plan to determine whether the Guide is being implemented as proposed. That 
plan should include methods to measure whether or not hazardous medications are being 
correctly identified and labeled by pharmacy, hazardous medications are being 
communicated as being hazardous, the correct PPE is being used, waste management 
requirements are being followed, site specific hazardous medication management 
processes are followed, and incidences of exposures to hazardous medications are 
tracked. The development of an implementation and evaluation plan will be critical to the 
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success of the Guide to control HCWs’ exposure to hazardous medications, and enhance 
worker and patient safety in the SLS.  
Conclusion 
 
In completing this practicum project the complex issue of how to support the 
implementation of the Hazardous Medication Personal Protective Equipment Guide and 
List in the SLS was identified and evaluated. This was achieved by completing a 
comprehensive review of the literature, consultations with key informants, an 
environmental scan, and a critical appraisal of the Guide. From this work, a number of 
recommendations were developed to improve the quality and implementability of the 
Guide. Implementing those recommendations will support the health and wellbeing of 
healthcare providers involved with hazardous medication management, which will in turn 
optimize outcomes at the level of the employee, the patient, and the healthcare system as 
a whole. In conclusion, the Hazardous Medication Personal Protective Equipment Guide 
and List is an excellent quality CPG that can be used as a clinical practice guideline to 
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Clinical practice guidelines (CPGs) are statements that guide health care workers 
(HCWs) when making decisions about appropriate care in specific situations, and are 
especially important in situations that affect patient safety. As outlined in the 
Occupational Health and Safety (OHS) Code; an employer is responsible to assess a 
worksite for existing and potential hazards and take measures to eliminate or control 
those hazards (Government of Alberta, 2018). In an effort to reduce or eliminate workers’ 
exposure to hazardous medications, and enhance worker and patient safety, Alberta 
Health Services (AHS) developed the Hazardous Medication Personal Protective 
Equipment Guide and List (2018), henceforth referred to as the Guide.  
There is a need to critically appraise this new Guide and to determine the quality 
of the document as a CPG for HCWs caring for adults in the Supportive Living setting 
(SLS). This literature review will examine the current literature as it relates to the 
development and evaluation of CPGs. Specifically, it will examine the use of the 
Appraisal of Guidelines for Research and Evaluation Instrument (AGREE II) to assess 
the quality of- and guide the development and reporting of CPGs for handling hazardous 
medications. The questions guiding this review include: 1) What is the current literature 
as it relates to the development and evaluation of CPGs? and 2) Has the AGREE II 
Instrument been used to evaluate the quality of CPGs for handling hazardous 
medications?  
Search Strategy 
A search of the Cumulative Index of Nursing and Allied Health Literature and 
PubMed databases was completed using the terms: clinical practice guidelines, hazardous 
medications, AGREE II, occupational health and safety or occupational medicine or 
31 
 
workplace health and safety or occupational health nursing. A thorough review of the 
content of the AGREE Trust website was also completed. Results were limited to articles 
written in English with a publication date between 2010 and 2018 as version two of the 
AGREE Instrument was not released until 2010. Abstracts were reviewed for relevancy 
and any articles that met the exclusion criteria were discarded leaving seventeen articles 
for review. Exclusion criteria included: letters to the editor, those inaccessible through 
library holdings, and those that involved research using modified versions of the AGREE 
II Instrument.  
Of the seventeen articles screened, eight were either research articles or literature 
reviews. Those articles underwent a critical appraisal using the Public Health Agency of 
Canada’s (PHAC, 2014) Critical Appraisal Toolkit (see Appendix A). In reading the 
aforementioned articles, the Guideline Implementability for Decision Excellence Model 
(GUIDE-M) was identified as a relevant adjunct to the AGREE II. As such, two articles 
about the GUIDE-M were also screened into the review and underwent a critical appraisal 
(see Appendix B). The themes gleaned from this comprehensive review of the literature 
are summarized below and include: CPGs, the AGREE II Instrument (intent, research and 
development, use, applications, limitations), the GUIDE-M, and future research.  
Clinical Practice Guidelines 
 
There are a number of different terms used in the literature to describe CPGs. 
While the term CPG is the most commonly used term, alternatives include evidence based 
practice guideline, best practice guideline, or guiding practice resource to name a few 
(Anaya, Franco, Merchan-Galvis, Gallardo, & Cosp, 2018; Brouwers et al., 2010a; Dewa, 
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Trojanowski, Jose, & Bonato, 2016). For the purposes of this literature review, the term 
CPG will be used. Like the variation in terminology, there are also varying definitions of 
a CPG in the literature. However, despite this variation there are two key characteristics 
of CPGs consistently reflected in those definitions. The first is that CPGs are intended to 
aid clinicians in decision-making (Anaya et al., 2018; Brouwers et al., 2010c; Dewa et al., 
2016; Joosen et al., 2015; MacQueen et al., 2017). Some authors maintain the CPGs are 
also intended to guide patients’ decision making (Anaya et al., 2018; Brouwers et al., 
2010a; Joosen et al., 2015; MacQueen et al., 2017).  
The second characteristic is that CPGs are developed based on a systematic 
review of the evidence (Anaya et al., 2018; Brouwers et al., 2010c; Joosen et al., 2015; 
MacQueen et al., 2017; Mambulu-Chikankheni, Eyles, Eboreime, & Ditlopo, 2017). It is 
this requirement that differentiates CPGs from consensus statements, expert advice, and 
standards (Dewa et al., 2016). Perhaps the most widely cited definition of a CPG from the 
literature is that of Woolf, Grol, Hutchinson, Eccles, & Grimshaw (1999) who define 
CPGs as, “systematically developed statements to assist practitioner and patient decisions 
about appropriate healthcare for specific clinical circumstances” (p. 528). In addition to 
the fact that this is the most commonly referenced definition, it is also the definition 
accepted by the AGREE Enterprise and therefore it is the definition used for the purposes 
of this literature review.  
Despite variation in terminology and definitions, there is consensus on the value 
of CPGs. CPGs are viewed as essential tools to summarize and translate the best available 
scientific evidence into practice (Joosen et al., 2015). CPGs serve to inform clinical 
decision making and diminish inappropriate clinical discrepancies thus optimizing patient 
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care, supporting the efficient use of resources, and promoting a positive attitude among 
practitioners (Anaya et al., 2018; Bragge et al., 2014; Brouwers et al., 2010c; Dewa et al., 
2016; Mambulu-Chikankheni et al., 2017). Furthermore, CPGs are useful to inform 
policy-, system-, and population- related decisions (Bragge et al., 2014; Brouwers et al., 
2010a; Brouwers et al., 2010c; Dewa et al., 2016; Mambulu-Chikankheni et al., 2017). It 
is of vital importance to note that the potential benefits of CPGs are directly related to the 
quality of the guideline itself (Brouwers et al., 2010c). The quality of CPGs is defined as 
“the confidence that the potential biases of guideline development have been addressed 
adequately and that the recommendations are both internally and externally valid and are 
feasible for practice” (AGREE Trust, 2013, p. 16). Bragge et al. (2014) caution that CPGs 
of low quality can lead to ineffective, wasteful, and even harmful practices that negatively 
affect outcomes at the level of the patient and the healthcare system. This is concerning 
given the numerous references from the literature highlighting the varying quality of 
CPGs and the fact that many guidelines fail to meet even basic standards (Brouwers et al., 
2010a; Brouwers et al., 2010c; Dewa et al., 2016; Makarski & Brouwers, 2014).  
Appraisal of Clinical Practice Guidelines 
 
The AGREE II is one established instrument that provides a systematic 
framework to critically appraise the quality of CPGs such as the Guide. The AGREE II 
Instrument, originally developed by an international team of guideline developers and 
researchers, has been translated into over 33 languages, is cited in over 600 publications, 
and has been endorsed by numerous health care organizations worldwide including the 
World Health Organization (Makarski & Brouwers, 2014). The AGREE II Instrument 
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was developed by the AGREE Collaboration to address the issue of the high variability in 
the quality of CPGs by providing a framework to critically analyze their quality. An 
assessment of the quality of a CPG requires an evaluation of the methods used for 
development, the components of the final recommendations, and the variables influencing 
the uptake of those recommendations. In addition to providing a framework for the 
assessment of the quality of CPGs, the AGREE II Instrument also provides a 
methodological strategy to guide CPG development and provides direction as to what and 
how information should be reported in CPGs (AGREE Trust, 2017).  
AGREE II Instrument 
 
The original AGREE Instrument was released in 2003 and was comprised of 23 
items falling under six quality domains (AGREE Trust, 2017). To improve the reliability 
and validity of the AGREE Instrument and support its use by end users, the AGREE 
Collaboration conducted a two part research study. In the first part of the study, Brouwers 
et al. (2010a) employed a mixed method design where participants were asked to use the 
new AGREE items to evaluate a CPG based on a new seven point scale, complete three 
outcome measures related to guideline adoption, provide feedback on the instrument’s 
usefulness, and identify areas in the instrument requiring improvement. Brouwers et al. 
(2010a) found that: 1) the psychometric properties of the new seven point Likert scale 
were promising, 2) quality ratings of the AGREE domains were good predictors of 
outcomes associated with guideline implementation, and 3) participants found the 
AGREE items and domains to be useful. In the second part of the study, Brouwers et al. 
(2010b) assessed the construct validity of 21 of the AGREE items and evaluated the new 
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manual. Brouwers et al. (2010b) were able to establish the construct validity of the 21 
items and confirm that the instructions for the new manual were appropriate, easy to read, 
and instilled confidence to use the tool among participants. Several changes were made to 
the instrument based on the aforementioned study findings leading to the creation of the 
AGREE II in 2010. Refinements included; availability of the user’s manual as a 
reference, changes to the items constituting the instrument, and a new 7 point response 
scale (Brouwers et al., 2010c).  
Composition of AGREE II 
 
Version two of the AGREE Instrument is comprised of 23 items that fall under 6 
different quality domains in addition to two global rating items intended to capture the 
quality of the overall assessment of the CPG. The first quality domain, Scope and 
Purpose, addresses the overall intent of the CPG, the specific questions it addresses, and 
the target population. The second domain, Stakeholder Involvement, considers whether or 
not the relevant stakeholders were involved in the development of the CPG and if the 
perspective(s) of the intended users are reflected in it. The third domain, Rigor of 
Development, evaluates the process used to gather and synthesize the evidence, formulate 
recommendations, and update those recommendations. The fourth domain, Clarity of 
Presentation, pertains to format, structure, and language used in the CPG. The fifth 
domain, Applicability, considers implementation barriers/facilitators as well as the 
financial implications of instating the CPG. The sixth domain, Editorial Independence, 
addresses whether or not the recommendations made in the CPG were unduly biased. 
Finally, the Overall Assessment section includes a rating of the overall quality of the 
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guideline and a rating of whether the guideline is recommended for use (AGREE Trust, 
2017).  
Using the AGREE II to Critically Analysis Clinical Practice Guidelines 
  
Owing to the aforementioned research conducted by Brouwers et al. (2010b), the 
AGREE II User’s Manual was developed to support the use of the AGREE II Instrument. 
That manual outlines the type of CPGs that can be assessed using the instrument, 
appraisers who should use the instrument, the number of appraisers required, how to 
complete the scoring, and the interpretation of the scoring. In their study, Brouwers et al. 
(2010b) found that the new user’s manual allowed even novice appraisers to apply the 
AGREE II Instrument with confidence to the critical analysis of many types of CPGs. 
The AGREE II Instrument was intentionally designed to be a generic tool with 
widespread usability. As such, the instrument can be used for many different types of 
CPGs developed at the local, regional, national, and even international level. It is suitable 
to appraise CPGs in any health or disease area targeting any steps of the health care 
continuum including health promotion, public health, screening, diagnosis, treatment, or 
intervention. Furthermore, the AGREE II Instrument can be used for paper or electronic 
CPGs. Finally, the instrument can be applied to original CPGs or to update existing CPGs 
(AGREE Trust, 2017).  
Appraisers  
 
The generic design of the AGREE II means the instrument can be used by a wide 
variety of different appraisers including: frontline healthcare providers appraising a 
guideline before incorporating it into their practice, guideline developers requiring 
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methodological guidance or an appraisal framework, policy makers needing to select a 
quality CPG, and even educators requiring a teaching aid to enhance others’ ability to 
appraise or develop guidelines. To support the reliability of any quality assessment 
process using the AGREE II Instrument, it is recommended that at least two and 
preferably four appraisers rate the guideline (AGREE Trust, 2017). Based on this review 
of the literature, anywhere from two to six appraisers performed the appraisal. It is 
estimated that each appraisal of a CPG will take an average of 90 minutes per appraiser to 
complete (Brouwers et al., 2010c). 
Likert Rating Scales  
 
Each of the 23 items on the AGREE II Instrument is rated using a 7 point Likert 
scale (Brouwers et al., 2010c). A rating of 1 represents a poorly defined concept or a lack 
of information and a rating of 7 indicates exceptional quality in that all of the criteria 
outlined for that item have been met. A score between 2 and 6 means that the reporting of 
the item does not fully meet the outlined criteria. The more criteria that a CPG meets the 
higher the individual item scores and associated domain scores. Although it is 
discouraged, there are circumstances where certain items need to be excluded from the 
appraisal process because they are not applicable to a certain CPG. In these situations the 
appraiser cannot just indicate “not applicable” on the tool. Instead, the item should either 
be skipped with modifications made to the domain score calculations, or rated as a 1 with 
rationale provided in the notes. In addition to the aforementioned 23 items on the AGREE 
II, there are two Overall Assessment items at the end of the instrument. The user is 
required to make an objective judgement of the quality of the guideline (rated on a scale 
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from 1-lowest possible quality to 7-highest possible quality) as well as make a 
recommendation for the use of the guideline (yes, yes with modifications, or no) (AGREE 
Trust, 2017).   
Scoring  
 
Individual scores for the 23 items are used to calculate a quality score for each 
domain by summing all of the scores within a domain and dividing by the maximum 
possible score for the domain. The resulting quality scores for each domain are 
represented as a percentage and are considered to be independent. That is to say, the 
individual domain scores are not to be aggregated into a single score of overall quality. 
Individual domain scores are useful to identify high quality guidelines worth endorsing, 
identify the strengths and weaknesses of a CPG, and to compare methodological quality 
among different guidelines. Interpretation of these scores requires a comparison against 
the quality threshold set by the appraiser. The quality threshold is the domain score 
percentage that represents a minimum level of acceptable quality. There is no standard 
quality threshold percentage endorsed in the AGREE II: User’s Manual due to a lack of 
empirical evidence establishing a relationship between specific domain scores to 
implementation outcomes. Instead, the manual maintains that quality thresholds must be 
defined based on stakeholder consensus taking into account the context in which the CPG 
is to be used (AGREE Trust, 2017).  
From the literature review, minimum quality thresholds were set between 50%-
70% (Anaya et al., 2018; Bragge et al., 2014; Dewa et al., 2016; Joosen et al., 2015; 
MacQueen et al., 2017; Shetty, Raaen, Khodyakov, Boutsicaris, & Nuckols, 2018). 
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Joosen et al. (2015) were the only appraisers to specifically assign quality thresholds for 
poor quality (30% or less), moderate quality (30-60%), and good quality (60% or above). 
Furthermore, the User’s Manual makes a number of suggestions for how domain quality 
scores can be interpreted, depending on the users’ objectives. One way is to prioritize one 
domain deemed to be of particular importance over the others. Another approach is to 
stage the appraisal whereby CPGs are screened in by first appraising the priority domain 
of interest before appraising the remaining five domains. Alternatively, the same- or 
different quality thresholds could be set for each domain. Finally, improvement 




With the AGREE II Framework serving as a foundation, the AGREE Reporting 
Checklist was created in 2016 (Brouwers, Kerkvliet, & Spithoff, 2016; Vernooij, Alonso-
Coello, Brouwers, & Martinez Garcia, 2017). Each AGREE II item was incorporated into 
a reporting guide intended to be used by CPG developers to improve the completeness 
and transparency of reporting (AGREE Enterprise, 2018). Brouwers et al. (2016) 
maintain that the checklist can be used prospectively during the drafting stage of a CPG 
and retrospectively as a quality assurance step after the document has been completed.  
To ensure the transferability and adaptability of the content constituting the 
AGREE Reporting Checklist, 15 guideline developers evaluated the checklist on its 
structure, ease of use, and its inclusion of all important reporting criteria, using a five 
point scale (Brouwers et al., 2016). Fourteen of the respondents indicated that the 
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required reporting criteria was reflected in the checklist, 13 indicated that they felt it 
would be useful for new and experienced CPG developers, and 13 reported that they 
themselves would use the checklist. Vernooij et al. (2017) then built upon the work of 
Brouwers et al. (2016) to develop a Checklist for the Reporting of Updated Guidelines 
(Check Up) intended to be used by CPG developers, users, and appraisers. Check Up 
supports the need to regularly review and update CPGs in order to assure trustworthiness 
by outlining the preferred reporting items for updating these documents (Vernooij et al., 
2017). Again, the checklist is based on the AGREE II Framework and consists of 16 
items that address: 1) presentation of the updated CPG, 2) editorial independence, and 3) 
the methodology of the update process (Vernooij et al., 2017). Both of the 
aforementioned checklists are designed to complement, not compete with, the AGREE II 
Instrument.  
Applications of the AGREE II 
 
 As previously discussed, the AGREE II Instrument was designed to provide a 
framework for assessing the quality of CPGs as well as to guide the development and 
reporting of CPGs (AGREE Trust, 2017). Brouwers et al. (2010a) maintain that these 
functions of the AGREE II make it the ideal tool to be incorporated into CPG 
development protocols and reporting templates, to compare and contrast CPGs that are 
candidates for endorsement, to inform policy related decisions, to define reporting 
requirements for CPGs submitted for journal publication, and to serve as a framework for 
reaching consensus regarding methodological and reporting requirements for 
transnational cooperation. Many articles reflecting an application of the AGREE II were 
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found in this literature review, the vast majority of which involved the use of the tool for 
appraisal. None of the articles involved the use of the AGREE II Instrument to guide the 
reporting of CPGs.   
Development of Guidelines  
 
The only article found from a comprehensive review of the literature that involved 
the use of the AGREE II for the development of a CPG was that written by Besselaar et 
al. (2017). Besselaar et al. reported on the work of six Dutch orthopedic surgeons who 
collaborated with a parents association to develop a CPG for the diagnosis and treatment 
of primary idiopathic clubfeet in children. Although this was not a research article, the 
authors offer support for the use of AGREE II for CPG development. Most importantly, 
the authors report that the application of this framework ensured that optimal 
collaboration between all relevant stakeholders (medical professionals, patients, and 
parents) occurred. Also of importance to note is that the AGREE II Tool served to direct a 
systematic review of the literature from which the recommendations contained in the 
guideline were based. However, the authors do note a limitation of the AGREE II 
Instrument in that it is not intended to be used to appraise the quality of scientific 
evidence (Besselaar et al., 2017). For this the authors made use of the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) method 
(Besselaar et al., 2017). Unfortunately, the authors do not address if and how the tool 
impacted the reporting of the CPG. This is unfortunate as transparency in describing how 
CPGs are developed is important for a quality appraisal and also to provide important 
contextual information that may explain variations in content from other guidelines 
(Dewa et al., 2016).       
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Appraisal of Clinical Practice Guidelines  
The vast majority of articles retrieved in this literature review involved the 
application of the AGREE II Instrument to appraise CPGs. One article reported on the 
appraisal of a single CPG while the others involved an appraisal and comparison of as 
many as 21 CPGs. In each case, the authors identified inconsistencies in the quality of the 
guidelines, including inconsistencies from one guideline to another and inconsistencies in 
domain scores within individual guidelines. Numerous recommendations to improve the 
quality of CPGs can be found in the literature based on these findings.  
Domain quality ratings. Despite the inconsistencies in quality within and among 
CPGs, a review of the literature did reveal consistency in those domains that typically 
scored highest and those that typically scored lowest. The domain that most consistently 
scored the highest quality rating was the Scope and Purpose domain. In their critical 
appraisal of four CPGs, Mambulu-Chikankheni et al. (2017) found that the Scope and 
Purpose domain had the highest domain quality score average at 89%. Likewise, in their 
systematic reviews, MacQueen et al. (2017), Joosen et al. (2015), Dewa et al. (2016), and 
Anaya et al. (2018) appraised CPGs and found this to be the top rated domain for quality. 
That is to say that across AGREE II appraisals of 56 different CPGs, Scope and Purpose 
was consistently the highest rated quality domain. Another domain that consistently 
received high quality scores was Clarity of Presentation. In fact, in Shetty et al. (2018) 
report on their use of the AGREE II to appraise the quality of a disability CPG, Clarity of 
Presentation received the highest domain score of 75%. Interestingly, this was also the 
second highest rated domain from MacQueen et al., Mambulu-Chikankheni et al., and 
Dewa et al.’s CPG appraisals.  
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The domain that was consistently rated the lowest in the literature was 
Applicability. In their systematic review of 11 CPGs, Bragge et al. (2014) found that 
Applicability was the lowest scoring domain with a median of 3.1%. The authors of three 
other systematic reviews, representing appraisals of 49 CPGs, also concluded that this 
was the lowest scoring quality domain (Anaya et al., 2018; Dewa et al., 2016; MacQueen 
et al., 2017). The second domain that was consistently rated low was Editorial 
Independence. In their critical appraisal, Mambulu-Chikankheni et al. (2017) found that 
the quality scores for this domain were the lowest ranging from 9-20%. Based on their 
systematic review involving an appraisal of 14 different CPGs, Joosen et al. (2015) also 
found Editorial Independence to be the lowest rated domain with an average quality score 
of 31%. Similarly, Bragge et al.’s appraisal of 11 CPGs revealed that this domain had the 
second lowest median of 20.8%. Given the pattern of consistently low quality domain 
scores presented above, it is not surprising that the recommendations made in the 
literature focus on strategies to improve the Applicability and Editorial Independence of 
CPGs by applying the AGREE II in the development phase.  
Applicability. This domain emphasizes the need to consider the implementation 
barriers/facilitators as well as the financial implications of instating a CPG (AGREE 
Trust, 2017). Based on the findings of their appraisals, Shetty et al. (2018), MacQueen et 
al. (2017), Bragge et al. (2014), Joosen et al. (2015), Anaya et al. (2018), Mambulu-
Chikankheni et al. (2017) and Dewa et al. (2016) all conclude that considering the 
implementability of a CPG in the development phase is of utmost importance. Shetty et 
al. argue that a failure to do so will inevitably hamper the adoption of a CPG and prevent 
the desired changes from being realized. In alignment with the AGREE II Framework, 
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MacQueen et al. and Bragge et al. maintain that advice and/or tools on how guideline 
recommendations can be put into practice must be explicitly addressed within the CPG 
itself. Shetty et al. and Bragge et al. provide a number of examples of such 
implementation strategies including education, training materials, reminders, 
computerized decision support, consultation, outreach visits, audits and feedback, peer 
review consultation, continuous quality improvement, and incentives. 
Editorial Independence. This domain focuses on whether or not the 
recommendations made in a CPG are unduly biased (AGREE Trust, 2017). Based on the 
findings of their critical appraisals, Shetty et al. (2018), MacQueen et al. (2017), Bragge 
et al. (2014), and Mambulu-Chikankheni et al. (2017) all conclude that improvements are 
needed to improve the quality of reporting of conflicts of interest which in many cases is 
poorly done or not even documented at all. MacQueen et al. argue that such disclosures 
are essential to ensuring greater safeguards to minimize competing interests thus ensuring 
CPG independence from external forces. Mambulu-Chikankheni et al. go further to 
highlight that while every effort to minimize conflicts of interest should be exhausted, 
some are inevitable and in such cases CPG developers must provide a justification for 
same.  
 Miscellaneous. While the majority of recommendations made were related to the 
Applicability and Editorial Independence domains, there were areas for improvement 
identified that fall under other domains. Although the Stakeholder Involvement domain 
typically received moderate quality ratings on average, Shetty et al. (2018), MacQueen et 
al. (2017), and Bragge et al. (2014) called for the need to improve the stakeholder 
engagement item within this domain by demonstrating due considerations to the views 
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and preferences of the target population (e.g. patients, members of the public, etc.). Shetty 
et al. and Bragge et al. also made a recommendation to improve the Rigor of Development 
scores among CPGs by outlining a specific procedure and schedule for updating the 
document to ensure that the recommendations within it remain current. 
Limitations of AGREE II 
 
A number of limitations of the AGREE II Instrument were identified in 
completing this literature review. The most widely cited limitation is the fact that the tool 
is intended to be used to evaluate the methodological quality of CPG development, not 
the clinical appropriateness or validity of the recommendations within it (Anaya et al., 
2018; Bragge et al., 2014; Brouwers et al., 2010c; Joosen et al., 2015; MacQueen et al., 
2017). There are however other tools cited in the literature that serve as a framework for 
assessing the quality of evidence contained within a CPG, most common is the GRADE 
method (Besselaar et al., 2017; MacQueen et al., 2017). Both Besselaar et al. (2017) and 
MacQueen et al. (2017) employed the GRADE method along with the AGREE II 
Instrument as complimentary frameworks. Other limitations of the AGREE II are that it is 
not intended to appraise the quality of guidance documents that address health care 
organizational issues and it has not been formally evaluated as a tool to appraise health 
technology assessments (AGREE Trust, 2017). Additionally, the AGREE II does not 
provide a means to assess the end user’s adherence to a CPG in practice nor evaluate the 
clinical impact of the guideline (Joosen et al., 2015). Finally, the instrument does not 
provide guidance regarding how the CPG should be implemented (Brouwers et al., 2010c; 





In light of the aforementioned limitations of the AGREE II Instrument, the 
AGREE Research Collaboration set out to develop an additional tool that would serve to 
support the implementability of CPGs. The GUIDE-M is a framework of intrinsic factors 
affecting the implementability of CPGs that was developed in 2015 (AGREE Enterprise, 
2018). According to Brouwers, Makarski, Kastner, Hayden & Bhattacharyya (2015), 
implementability refers to “characteristics of guidelines that promote their use, and these 
may be both intrinsic attributes- those related to the guideline itself- or extrinsic 
attributes- those related to the action of the healthcare system in which the guidelines are 
used” (p. 2). Brouwers et al. (2015) maintained that the development of a tool to support 
the implementability of CPGs was essential for two reasons. First, the full potential of 
CPGs cannot be realized when the documents are poorly implemented (Brouwers et al., 
2015). When it comes to the intrinsic attributes of a CPG such as what and how the 
content is presented, relatively minor changes in CPG development should prove a low 
cost strategy that will yield substantial benefit (Brouwers et al., 2015). Second, at the time 
there was no other resource that incorporated a comprehensive approach involving all of 
the attributes relevant to guideline implementability, available for use (Kastner et al., 
2015).  
By means of a Realist Review, a survey of 248 members of the worldwide CPG 
community, and content analysis, a framework of intrinsic factors affecting the 
implementability of CPGs titled the GUIDE-M, was developed. This conceptual model 
reflects an evidence-informed international and multidisciplinary perspective to CPG 
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implementability. The framework consists of six layers of components intrinsic to CPGs 
that are related to implementability. The top layer of the GUIDE-M consists of three core 
implementability tactics with their associated domains, sub-domains, attributes, sub-
attributes, and elements comprising the remaining five levels (AGREE Enterprise, 2018).  
The three tactics include the following: Developers of Content, Creating Content, 
and Communicating Content (Brouwers et al., 2015). The Developers of Content tactic 
outlines the types and characteristics of the people required to make up a comprehensive 
group of CPG developers, the expected knowledge and credentials required of said 
developers, and the need to disclose any competing interests (Brouwers et al. 2015). The 
Creation of Content tactic outlines the need for widespread stakeholder involvement, the 
appropriate synthesis of evidence, consistent reporting of CPG elements, maintaining the 
currency of guidelines, the need to supplement scientific evidence with considered 
judgement, and making due considerations for the feasibility of implementing the 
recommendations (Kastner et al., 2015).  
Finally, the Communication of Content tactic involves fine tuning the CPG 
message and format (Kastner et al., 2015). The message should be written in such a way 
that it is clear, simple, and persuasive and the format should consist of key headings (e.g. 
purpose, methods, recommendations) and be presented in multiple versions to address the 
needs of different users (Brouwers et al., 2015). The core assumption of the model is that 
an improvement in the quality of any of these intrinsic components will improve 
implementability by increasing the acceptability, ability to drive action, feasibility, and 
uptake of CPGs (AGREE Enterprise, 2018).  
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Based on members of the international CPG community’s ratings of the structure 
and operational definitions of the GUIDE-M components, Brouwers et al. (2015) 
concluded that the model is a logical, relevant, and appropriate conceptualization of 
guideline implementability. Brouwers et al. (2015) maintain that the GUIDE-M can be 
used in a number of ways. It can be used to create documents with high implementability, 
to help consumers of guidelines, and to identify areas for further research (Brouwers et 
al., 2015). The goal of applying the GUIDE-M is to improve the implementability of 
CPGs thus improving the uptake of same and the quality of care delivered ultimately 
resulting in improved outcomes at the individual and health care system level (Brouwers 
et al., 2015). The AGREE Collaboration is currently in the process of refining a tool 
designed to evaluate the quality and implementability of CPGs based on the GUIDE-M 
titled the AGREE Recommendation Excellence (AGREE-REX) (AGREE Enterprise, 
2018). This tool is currently not available to the public.  
Future Research 
From this literature review, a number of areas with respect to the AGREE II 
Framework were identified as requiring further research. First, the AGREE II Instrument 
requires further empirical testing to reproduce the findings from Brouwers et al. (2010a, 
2010b) studies investigating the construct validity and reliability of the instrument. This 
research should incorporate larger sample sizes, include an assessment of all 23 items 
comprising the tool, and should be conducted by researchers independent of the AGREE 
Research Collaboration to eliminate the potential influence of researcher bias. 
Additionally, there are currently no studies that have yielded empirical data to link 
specific quality threshold scores with specific implementation or clinical outcomes. This 
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makes it difficult for users of the AGREE II Instrument to select quality thresholds to 
differentiate between CPGs of high, moderate, and low quality.  
Another area for future research is with respect to the GUIDE-M. Although the 
GUIDE-M was the product of a rigorous, systematic, and transparent methodology, there 
has been no empirical testing of the attributes proposed within the model in supporting 
CPG implementability. Finally, it is important to note that validity and reliability testing 
of the AGREE-REX as a tool to assess the quality and implementability of a CPG is 
currently underway (AGREE Enterprise, 2018). 
ARGEE II and Hazardous Medications 
Unfortunately, there were no examples of an application of the AGREE II 
Instrument for the development and/or evaluation of a CPG dealing with exposure to 
hazardous medications found in the literature. However, sufficient evidence has been 
obtained from the literature to support the use of this tool to conduct an appraisal of the 
AHS Hazardous Medication Personal Protective Equipment Guide and List. First, the 
Guide meets the AGREE II: User’s Manual (2017) definition of a CPG. The writer also 
qualifies as an intended user as defined in the user’s manual although at least one other 
appraiser is technically required to validate the findings (AGREE Trust, 2017). Finally, 
there were three different articles found in the literature where the authors made use of 
the AGREE II Instrument to appraise OHS related CPGs similar to the Guide.   
Given the fact that the AGREE II Instrument does not provide guidance regarding 
how a CPG should be implemented (Brouwers et al., 2010c; Joosen et al., 2015), the 
writer will also make use of the GUIDE-M. While it would have been ideal that the 
GUIDE-M be used in the development stage of the Guide to support implementability 
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(Dewa et al., 2016), the conceptual model will still prove useful after the fact. The 
GUIDE-M will serve as a theoretical point of reference in completing the critical 
appraisal and will inform the development of recommendations to support the 
implementation of the Guide at other SL facilities. 
Conclusion 
 
From this comprehensive review of the literature the tremendous potential of 
CPGs to inform clinical decision making, therefore optimizing outcomes, became 
apparent (Anaya et al., 2018; Bragge et al., 2014; Brouwers et al., 2010c; Dewa et al., 
2016; Mambulu-Chikankheni et al., 2017). Furthermore, the AGREE II was established 
as a valuable framework to appraise the quality of CPGs as well as guide the development 
and reporting of same (AGREE Enterprise, 2018). It was very apparent from the 
numerous articles reporting on the use of the AGREE II Instrument to appraise CPGs, 
that there is significant variability in the quality of guidelines, with many failing to meet 
even basic standards. This represents a significant problem as the poor quality of a CPG 
limits the potential benefits of the document (Brouwers et al., 2015). 
Despite the fact that the AGREE II offers a methodological strategy for CPG 
development, there was only one article found in this review demonstrating this 
application of the instrument (Besselaar et al., 2017). This, along with the fact that the 
appraisals of existing CPGs showed highly variable quality scores, highlights the 
importance of using the AGREE II Framework in the development stage. Although it 
would have been ideal to apply the AGREE II Framework during development, the writer 
can still use the AGREE II Instrument to conduct an appraisal of the Hazardous 
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Medication Personal Protective Equipment Guide and List. Furthermore, the GUIDE-M 
will be used to inform the critical appraisal and subsequent recommendations for future 
implementations of the Guide. The goal is that the appraisal and recommendations will 
increase the quality and implementability of the Guide thus optimizing outcomes at the 
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1. Background  
Health care workers (HCWs) are at risk for occupational exposure to hazardous 
medications, which can result in adverse health effects. As outlined in the Occupational 
Health and Safety (OHS) Code; an employer is responsible to assess a worksite for 
existing and potential hazards and take measures to eliminate or control said hazards 
(Government of Alberta, 2018). To control workers’ exposure to hazardous medications, 
and enhance worker and patient safety, Alberta Health Services (AHS) developed the 
Hazardous Medication Personal Protective Equipment Guide and List (2018). Prior to the 
implementation of this Guide, HCWs referred to the Cytotoxic Drug Manual 
Administration and Handling Guidelines (AHS, 2013) to identify the required safety 
measures when working with cytotoxic medications. Both the Guide (AHS, 2018) and the 




The Hazardous Medication Personal Protective Equipment Guide and List 
deviates from the existing Cytotoxic Drug Manual Administration and Handling 
Guidelines in a number of ways, which could have significant implications for HCWs 
caring for adults living in the community. The Manual lists the cytotoxic drugs that 
necessitate added control measures when being handled whereas the new Guide contains 
an extensive list of all hazardous medications adopted directly from the National Institute 
for Occupational Safety and Health (NIOSH). The NIOSH list includes cytotoxic 
medications as well as those that are teratogenic, genotoxic, toxic to organs, and those 
that mimic other known hazardous medications (AHS, 2018). As such, the list of 
medications representing an occupational hazard under the new Guide is significantly 
longer and includes common medications such as carbamazepine, estrogen/progesterone 
containing medications, clonazepam, valproic acid, and warfarin.  
Following a province wide roll out of the Hazardous Medication Personal 
Protective Equipment Guide and List in January of 2018, a number of questions and 
concerns came forward regarding how this Guide could be implemented in the Supportive 
Living setting (SLS). Barriers to implementing the new Guide included the increase in 
costs for more personal protective equipment (PPE) and spill kits, a lack of resources and 
processes for the disposal of biohazardous wastes, and issues ensuring hazardous 
medication risks are communicated to all HCWs. These barriers could have a major 
impact on the implementation of the Guide in the SLS. To date, the only SL facility in 
AHS known to have fully implemented the Guide is the test site.  
The overall purpose for this practicum project is to conduct a critical appraisal of 
the Guide using the Appraisal of Guidelines for Research and Evaluation Instrument II 
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(AGREE II). This appraisal will serve to determine the value of the Hazardous 
Medication Personal Protective Equipment Guide and List as a clinical practice guideline 
for HCWs caring for adults living in the SLS. Furthermore, consultations with key 
informants at the test site will serve to reveal essential information about the 
implementation of the Guide in the SLS. In order to collect information from key 
informants about the Guide and apply that knowledge to the appraisal of the Guide, 
consultations were conducted. The specific objectives of the consultations were to: 
1. Identify the current implementation plan for the Guide. 
2. Identify the key informants’ perception of the Guide.  
3. Examine barriers and facilitators that affect the implementation of the Guide.  
4. Identify strategies and recommendations to support the successful implementation of 
the Guide.  
2. Sample and Data Collection 
 
A total of ten interviews were conducted, one on one, with key informants. Six 
interviews took place in person in a private office and four interviews took place via 
telephone. Interviewees consisted of Managers, a Team Lead, HCWs, a pharmacist and 
representatives from the Continuing Care Hazardous Medication Committee and a 
Continuing Care Senior Workplace Health and Safety Advisor. Unfortunately, there were 
no nutrition and food services workers or linen and environmental services workers 
available for interviews. Interviews with the HCWs were arranged by the site Manager 
and all other interviews were booked by the author. Interviews were booked for a time 
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that was convenient for the informant. All interviews were conducted using a semi-
structured Interview Guide. Each interview began with the author introducing herself, 
explaining her role, the objectives of the practicum project, and the specific objectives for 
the interview. The author also explained how the data would be analyzed and outlined the 
plan to use the information collected. Consent to participate was obtained from each 
participant before beginning the interview. Data collection continued until a critical point 
of data saturation was reached. 
3. Data Management and Analysis 
Notes were taken throughout the interview and immediately after each 
consultation the writer reflected upon the findings. Findings from the interviews, and the 
reflections upon same, then underwent content analysis whereby common themes in 
relation to each interview question were identified and analyzed. 
4. Ethical Considerations 
Based on the results of the Health Research Ethics Authority Screening Tool, 
Research Ethics Board review was not required for these consultations as the purpose of 
the project is quality/evaluation. However, permission to conduct the practicum project, 
which included the implementation of the consultation plan, was obtained from the 
writer’s practicum supervisor from the Memorial University of Newfoundland, the SLS 
Program Manager, and the site Manager.  
Although approval from a Research Ethics Board was not indicated for this 
consultation plan, a number of steps were still implemented to protect the rights of the 
key informants. First, free and informed consent to participate was obtained from each 
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key informant verbally. Each participant was given information in order to make an 
informed decision including: the purpose of the evaluation, that participation was 
voluntary, a description of participant responsibilities and time commitment required, the 
type of information that was to be collected, the potential risks and benefits of 
participation, how findings would be disseminated, measures that would be taken to 
safeguard information collected, the writer’s contact information, and the participant’s 
right to withdraw at any time (Government of Canada, 2014). Second, steps were taken to 
secure the data collected. Data recorded during and after the interviews was stored in a 
locked filing cabinet only accessible to the writer. This data will be kept for two years 
after completion of the practicum at which point the paper copies will be shredded. Also, 
the confidentiality and anonymity of participants’ responses was maintained by removing 
any identifying information from the presented findings. 
5. Results 
Content analysis of the interview findings revealed common themes related to: 
informants’ perception of the guide (awareness and use), the factors that supported or 
hindered the implementation of the Guide, the current implementation plan, and strategies 
and recommendations to support the successful implementation of the Guide.  
Perception of the Guide 
Awareness. All of the key informants interviewed were aware of the existence of 
the new Hazardous Medication Personal Protective Equipment Guide and List. Six of the 
ten informants were aware that the Guide could be accessed on the AHS Insite while 
three others relied on paper copies that had been printed and made available to them in 
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the nursing station. Four of the participants were also aware that the Guide had been 
posted to the external AHS website which is accessible to members of the public and so is 
accessible by those non-AHS employees who are stakeholders in the hazardous 
medication management process (e.g. community pharmacies).   
Use of the Guide. All but one informant reported having used the Hazardous 
Medication Personal Protective Equipment Guide and List. Of the informants that have 
used the Guide, the way- and purpose- of using it varied. Five of the informants reported 
that they directly access the Guide, in its entirety, to use it. The other four informants who 
use it report that they do not access the complete Guide in their work. Three informants 
reported that they access only those portions of the guide relevant to their position and 
work. Relevant sections of the Guide, mainly the PPE and waste management posters, are 
printed and posted at the point of care. One key informant reported being able to access 
the hazardous medication list from his/her employer’s computer system, which has been 
uploaded with the applicable content.  
There was variation in the purpose for which the informants use the Guide. Five 
of the informants report using the Guide to identify the control measures required to 
reduce their risk of exposure to hazardous medications. Two of the informants report 
using the Guide as a reference in order to fulfill their responsibilities in preventing 
exposure to hazardous medication within the SLS. Two of the ten informants report using 




Facilitators for Implementation 
Informants identified a number of factors associated with the Hazardous 
Medication Personal Protective Equipment Guide and List that supported its successful 
implementation at the test site. Five of the informants who have used the Guide report 
that it is easy to use and self-explanatory. Two informants elaborated that the Guide is 
broken down into tasks which makes it easy to use. One informant expressed that the 
comprehensiveness of the Guide is a real facilitator for implementation. Another pro of 
the Guide identified by three of the informants was that it contains posters that provide 
direction regarding PPE use and/or waste management requirements that can easily be 
printed and posted at the point of care for HCWs to refer to. Two informants identified 
the fact that the Guide contains pictures of tasks, PPE, and waste management equipment 
and supplies as being a pro. Similarly, two informants identified the algorithm 
summarizing how to use the Guide as facilitating implementation. Two informants stated 
that a pro of the Guide was that the WHS Advisors and Medication Management Steering 
Committee were consulted in its development to support applicability and usability. 
Finally, one informant identified that the contact information provided within the Guide 
to the hazardous medication experts was a plus as it ensures users will know where they 
can go if they have more questions about the contents. 
Factors that Hinder Implementation 
 Informants identified a number of factors associated with the Hazardous 
Medication Personal Protective Equipment Guide and List that hindered the success of its 
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implementation. Four of the informants described the guide as “intense”, “robust”, or 
“overwhelming”, making it difficult to find the required information in a timely manner. 
One of these informants went further to criticize the already lengthy guide for containing 
numerous hyperlinks and references to additional documents that are also lengthy. While 
the overall Guide was criticized for being lengthy, three informants also criticized the 
inclusion of commonly prescribed medications such as warfarin, selective serotonin 
reuptake inhibitors, and risperidone. One informant stated “there is no scientific evidence 
that the drugs on the potential hazard list are in fact harmful when handled in low doses”. 
This informant felt that the previous list contained within the Cytotoxic Drug Manual 
Administration and Handling Guidelines was more appropriate because it only contained 
medications that were known hazards, described as “the big guns.”  
One informant expressed concerns that the comprehensive list of hazardous 
medications, particularly those that are potential or reproductive hazards, lends the Guide 
to conveying an inaccurate portrayal of the risk associated with these medications. That is 
to say, the Guide exaggerates the true risk associated with the medications falling within 
the potential and reproductive categories. Another participant felt that the extensive list 
could lead to complacency where essentially a HCW might see the same hazardous 
medication label on warfarin as on methotrexate and so think that the risk of handling the 
methotrexate is as low as handling warfarin, or vice versa. Another significant criticism 
coming from one informant was that the Guide was written as a clinical practice 
guideline, not a policy, which could create problems enforcing the recommendations.  
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Despite the fact that the Guide was criticized for being lengthy, a number of 
criticisms regarding a lack of direction were also brought forward. Two informants 
identified the fact that the Guide does not outline the roles and responsibilities of AHS 
HCWs and contracted service provider HCWs, with respect to following the Guide. In 
partnership situations where both AHS and contracted service providers are involved in 
the provision of care, the Guide does not indicate who is responsible for providing and 
paying for the cost of PPE and waste management equipment and services. One informant 
pointed out that the Guide was written from an acute care perspective and assumes the 
end users of the document are all AHS HCWs, which of course is not the case in the SLS. 
For example, the Guide shows pictures of the acceptable hazardous medication labels 
readily available in acute care but not available to community pharmacies. Further to this, 
two informants pointed out that they were not sure if the recommendations in the Guide 
apply to contracted service providers who have their own processes for hazardous 
medication management.  
Two informants criticized the Guide for failing to provide program level processes 
leaving programs without clear directions to meet the recommendations in the Guide (e.g. 
waste disposal). One informant pointed out that the Guide refers the user to contact their 
WHS Advisor for program specific processes for a specific task, which could result in a 
delay in receiving information. Key informants recommended the following content be 
added to the Guide: 1) specific spill kits recommended for use, 2) precautions required of 
clients/families potentially exposed to hazardous medications, and 3) direction regarding 
the selection of PPE where recommended PPE for the purposes of protecting a worker 
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from hazardous medication exposure contradict those required for infectious disease 
exposure.  
Current Implementation Plan  
Key informants reported that a number of different strategies were used in the 
current implementation of the Guide at the test site including education and site specific 
processes. One of the key strategies identified by seven of the participants was the 
education HCWs received about the Guide including an introduction to the Guide, a 
demonstration of the donning and doffing of PPE and a demonstration of how to draw up, 
administer, and dispose of a hazardous medication. Two informants also reported that 
HCWs responsible for the administration of cytotoxic medications, were also required to 
complete the Cytotoxic Medication Management e-module and test. Two other 
informants noted during their interviews that they had completed this e-module.  
One key informant also noted that during their orientation “buddy shifts”, their 
mentor provided information regarding the hazardous medication management process at 
the test site. She also noted that, HCWs who do not routinely administer hazardous 
medications do so under the guidance of an experienced nurse. Two informants reported 
that it was necessary to provide some education to the client/family who was receiving 
the hazardous medication that required PPE for administration. This was necessary to 
ease the client/family’s anxiety about the PPE use by HCWs. Finally, one informant 
spoke of efforts to continually promote awareness regarding the hazardous medication 
management process during change of shift report, checking with HCWs to answer 
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questions about the recommendations in the Guide, and ensuring that HCWs are aware of 
how to reach out if they have questions.  
Another strategy used to implement the Guide at the test site was to collaborate 
with community pharmacies supplying medications, to agree on a process for identifying, 
preparing, and packaging hazardous medications. Three informants report that at the test 
site they collaborated with the pharmacy to achieve this partnership. One of the three 
main pharmacies serving the site reported that they uploaded the NIOSH list into their 
computer system. The system then automatically printed the warning “HAZARDOUS 
MEDICATION” on the medication package, and the medication administration record. 
The pharmacy technicians also affixed the hazardous medication sticker to the drug 
package. The pharmacist then double checks to make sure the labeling is correct. It is 
noteworthy that the hazardous medication label does not specify whether or not the 
medication is a known, potential, or reproductive hazard.  
The next strategy used to implement the Guide at the test site was to develop an 
internal process for managing hazardous medications. A large part of this process 
involves the communication of hazardous medication related risks. Six of the informants 
reported that the following is the process for managing hazardous medications at the test 
site: 1) when medications arrive from pharmacy the nurse reviews them to identify if any 
are labeled as hazardous, 2) if a hazardous medication is identified the nurse refers to the 
Guide to determine if it is a known, potential, or reproductive hazard, 3) the nurse informs 
the other HCWs of the hazardous medication during shift report and by means of 
updating the Kardex with the hazardous medication label, and 4) the nurse prints the PPE 
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and waste management posters applicable to the hazardous medication identified in the 
Guide and posts them in the client’s individual medication cupboards in their rooms. The 
posters related to the required waste management processes are also posted in the client’s 
bathroom. If the client’s human waste poses a hazard the nurse would also communicate 
this to the site manager so other departments (e.g. environmental services) can be 
informed.  
One informant reported that the Case Manager is informed of clients who have 
been prescribed hazardous medications either by attending rounds, through report from 
the nurse, or by reviewing the medication administration records. The Case Manager then 
documents that the client is taking hazardous medications on the Safety Risk Assessment 
and Daily Living Support Plan Interventions on the care plan. Furthermore, five 
informants reported that for the one client receiving a known hazardous medication, the 
precautionary period for handling human wastes is communicated to the team via change 
of shift report and written on the Kardex. All five key informants reported that any 
articles contaminated with human wastes during the precautionary period are disposed of 
in the biohazard bin. One informant added that a professional waste disposal company 
provides the biohazardous bins and picks them up when they are full.  
Another implementation strategy that promoted the successful implementation of 
the recommendations from the Guide at the test site was obtaining the PPE and other 
equipment required for the management of hazardous medications, and making it readily 
available to the HCWs who need it at the point of care. Five of the informants reported 
that required PPE was stored in the client’s medication cupboard, and in the bathroom if 
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PPE was indicated for human waste management. One informant clarified that the nurse 
who identifies the hazardous medication is responsible for ensuring the required PPE is 
put in the client’s room and that each week the stock is replenished. Four of the 
informants reported that PPE has been readily available to them when needed. One 
informant reported that there have been cases where she has had to “track down” the PPE 
when it was needed.  
Strategies to Address Barriers to Successful Implementation  
The barriers to successful implementation of the Guide identified by the key 
informants at the test site were addressed by creating site-specific processes. Many of the 
challenges/barriers are related to the aforementioned cons of the Guide and include a lack 
of site specific processes, the long list of medications considered hazardous, level of 
exposure risk for HCWs and families, collaborating with pharmacy, and costs of PPE 
equipment.  
Site specific processes. Three informants identified that the lack of SL specific 
processes within the Guide posed a challenge to its implementation. Two of the 
informants agreed that this challenge was overcome by creating their own site-specific 
processes for hazardous medication management that complied with the requirements 
outlined in the Guide. This process is described above and according to two informants 
has had the added benefit of supporting the efficient use of the robust content and 
addressing the challenge of navigating and interpreting the Guide.  
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List of medications. An additional barrier identified by two informants was the 
new, long list of medications included on the hazardous medication list contained within 
the Guide. One informant pointed out that the length of the list makes it difficult to 
identify hazardous medications quickly. This informant felt the hazardous medication list 
contained within the Cytotoxic Drug Manual Administration and Handling Guidelines 
was a better guide for the SLS. Strategies to overcome this barrier include pharmacy 
uploading the list to their computer system so that medications that are hazardous are 
automatically flagged and educating HCWs on the new list in the Guide.  
Low risk medication. Another barrier to the implementation of the Guide at the 
test site, identified by three informants, was the fear of handling hazardous medications 
that were previously not considered to be hazardous. These informants reported that the 
education on the Guide and support provided to implement the recommendations from the 
Guide was sufficient to ease this worry and instill feelings of confidence among the 
HCWs in managing these medications. In addition to the initial response from HCWs to 
the Guide, three informants also reported that its implementation was intimidating and 
alienating for the clients taking the hazardous medications and their families and friends. 
Two of these informants reported that after they explained that the PPE was required to 
manage the occupational risks associated with hazardous medications, these concerns 
were addressed. One informant spoke of a client’s family’s concern that they themselves 
had been administering the same medication to the client for years without taking any 
precautions. The family was upset that they had not been cautioned to take measures to 
protect themselves. The informant explained that the client/family’s concerns were 
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addressed in part by providing some education about the hazard, exposure, and relative 
risk but obviously they were unable to remedy previous exposures.  
Collaboration with pharmacy. A number of additional challenges/barriers to the 
implementation of the Guide, unrelated to the perceived cons inherent to the document, 
were identified. First, collaborating with all pharmacy providers to ensure hazardous 
medications were identified and appropriately labeled was a challenge. Although most 
clients use the main pharmacy provider for the site, two informants reported that 
connecting with the other “smaller” community pharmacies and getting them “on board” 
required a lot of effort. However, both informants report that these efforts were successful 
as these smaller pharmacies are now identifying and labeling the medications 
appropriately.  
Another challenge/barrier identified by an informant was that the requirement to 
affix the hazardous medication sticker to the medication package, in addition to the 
labeling printed on the package via the computer system, was “cumbersome” and not a 
failsafe as it requires the pharmacy staff member to manually add the sticker. This 
informant also questioned if adding a second flag to the packaging indicating that it 
contains a hazardous medication is “overkill” and possibly creates an overreliance by 
HCWs on the element of the hazardous medication labeling process that is susceptible to 
human error (i.e. the manual addition of the sticker versus the automatic labeling by the 
computer system). The informant recommended doing away with the use of the 
hazardous medication sticker and relying solely on the label printed from the computer, 
which indicates “HAZARDOUS MEDICATION.” The informant also cautioned that a 
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process is required for any updates made to the hazardous medication list to be identified 
and uploaded into their computer system.  
Costs of PPE. Another challenge/barrier to the implementation of the Guide was 
the costs associated with providing PPE, waste collection receptacles, and spill kits. Four 
informants identified extra costs associated with the overuse of PPE (e.g. using additional 
PPE to handle the biological wastes of a client who previously received a known 
hazardous medication, even though the precautionary period was over). Four key 
informants reported that the cost associated with the overuse of PPE was addressed by 
improving the communication processes in place to identify the clients on hazardous 
medications, the required precautionary periods, and the PPE and waste management 
equipment needed. This topic was also addressed in the education provided to all HCWs 
on the Guide.  
One informant expressed a need to monitor the use of PPE on an ongoing basis to 
ensure it is used appropriately. In addition to the issue of cost, four informants identified 
the time it takes to don and doff PPE as a challenge/barrier. One informant explained that 
the time required to don and doff PPE was impacted by the availability of the required 
equipment at the point of care. Finally, one informant identified that a challenge 
associated with the implementation of the Guide, specifically the use of PPE as outlined 
within it, creates a significant amount of environmental wastes. However, key informants 




Prefilled medications. Another challenge/barrier that was encountered was in 
obtaining prefilled methotrexate syringes for injection. Two informants report that 
initially they were required to manually draw up the medication from a vial prior to 
administration, thus increasing their risk of exposure. One informant said that she looked 
into having the pharmacy provide pre-filled syringes but that it was not possible as the 
client could not afford the difference in price, approximately $400 a year. Fortunately, 
another informant reported that they were able to secure the client additional funding 
from Blue Cross for the pre-filled syringes which are now being provided.  
Organizational structure. The final challenge/barrier that informants encountered 
was a change to the organizational structure at the test site. Since the initial 
implementation of the Guide, another company has taken over the contract for nutrition 
and food services and linen and environmental services. This has created confusion as to 
which employer is responsible to supply the PPE for these workers. One strategy used to 
address this issue was to change the client’s housekeeping day to a day that falls outside 
of the precautionary period (if the client is taking a known hazardous medication) and 
therefore the management of any bodily wastes does not require additional PPE beyond 
routine precautions.  
Recommendations for Implementation   
During the consultations, key informants made a number of recommendations for 
the successful implementation and evaluation of the Guide:  
i) Develop site-specific processes for hazardous medication management.  
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ii) Assign an onsite clinical lead or resource person to assist HCWs to 
identify the control measures needed for each individual client taking 
hazardous medications.  
iii) Post PPE and waste management posters at the point of care.  
iv) Continue to consult with pharmacy to ensure the hazardous medication list 
has been uploaded into the computer dispensing system wherever possible 
and ensure a process is in place to update the list as necessary.  
v) Educate all HCWs about the Guide at orientation and through ongoing 
education sessions tailored to the needs of the HCWs.  
vi) Explore all HCWs, including contracted service providers, completing the 
Cytotoxic Medication Management e-module and test.  
vii) Reassure and educate clients and families about controls required for the 
safe management of hazardous medications and bodily wastes: provide 
initial and ongoing education and support to clients and families, including 
written education resources.  
viii) Collaborate with all pharmacy providers to ensure processes are in place to 
identify and label hazardous medications.  
ix) Ensure HCWs are knowledgeable about when and what equipment to use 
and audit the use of that equipment on an ongoing basis.  
x) Where possible, schedule housekeeping services on a day that falls outside 
of the precautionary period for hazardous medications.  
xi) Ensure the required PPE is available to all HCWs at the point of care.  
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xii) Explore pharmacy providing pre-filled syringes for injectable hazardous 
medications as needed and seek financial support from insurance 
companies to cover additional costs associated with pre-filled syringes. 
xiii) Clarify who is responsible for covering the costs associated with providing 
PPE and waste disposal equipment and services. 
xiv) Evaluate ongoing compliance to the Guide by conducting regular audits to 
ensure: hazardous medications are correctly identified and labeled by 
pharmacy, hazardous medications are identified and communicated as 
being hazardous amongst the facility staff, the correct PPE is being used, 
waste management requirements are being followed, and site specific 
hazardous medication management processes are followed.  
xv) Track exposure reports to identify incidences of exposures to hazardous 
medications (via My Safety Net for AHS HCWs).  
xvi) Involve HCWs in developing and implementing an evaluation plan for the 
Guide at all sites (e.g. focus groups). 
6. Conclusion 
 The results obtained from these consultations were used to complete the critical 
appraisal of the Hazardous Medication Personal Protective Equipment Guide and List. 
Data collected from informants regarding their awareness and use of the Guide, barriers 
to implementation, and strategies and recommendations to support implementation will 
prove vital in the formulation of final recommendations to support future implementation 
of the Guide.  
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Appraisal of a Hazardous Medication Personal Protective Equipment Guide and 
List for Health Care Workers Caring for Adults in the Community 
Interview Guide 
Information on the Project 
The overall goal of this practicum is to appraise the Hazardous Medication Personal 
Protective Equipment Guide and List (AHS, 2018). I am interested in your opinions about 
the Guide including the barriers and/or facilitators to implementing the Guide and your 
recommendations for strategies to successfully implement the Guide. Your participation 
is voluntary and you can withdraw at any time before or during the interview. This 
interview should take 15 to 20 minutes and you will be asked a series of questions about 
the Guide. Notes will be taken during this interview and your comments will remain 
anonymous. No identifying information will be used. The findings from this interview 
will be used to inform the practicum project and will be included in a final report that will 
be available in the Health Sciences Library.  
Do you agree to participate in this interview? 
Interview Questions 
1. Are you aware of the Hazardous Medication Personal Protective Equipment 
Guide and List? 
2. Do you and/or your colleagues/HCWs use the Guide?  
3. How was the Guide implemented at the test site?  
4. Did the implementation of the Guide go as planned?  
5. What evidence is there to show that the Guide was implemented at the test site?  
6. What were some barriers to the implementation of the Guide? 
7. How did you overcome these barriers in order to implement the Guide? 
8. What were some enablers that facilitated the implementation of the Guide?  
9. What do you think of the Guide? What do you like about it? What don’t you like 
about it?  








Health Research Ethics Authority Screening Tool 
 Question Yes   No 
1. Is the project funded by, or being submitted to, a research funding agency for a 




2. Are there any local policies which require this project to undergo review by a 
Research Ethics Board? 
 

 IF YES to either of the above, the project should be submitted to a Research 
Ethics Board. 








3. Is the primary purpose of the project to contribute to the growing body of 
knowledge regarding health and/or health systems that are generally accessible 















6. Is the project design and methodology adequate to support generalizations that 






7. Does the project impose any additional burdens on participants beyond what 







LINE A: SUBTOTAL Questions 3 through 7  2 
 
8. Are many of the participants in the project also likely to be among those who 










  10. Would the project still be done at your site, even if there were no opportunity to 






11. Does the statement of purpose of the project refer explicitly to the features of a 
particular program, 
Organization, or region, rather than using more general terminology such as 







12. Is the current project part of a continuous process of gathering or monitoring 
data within an organization? 
 
 
LINE B: SUBTOTAL  3 
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1. Brief Overview of the Project  
To control workers’ exposure to hazardous medications, and enhance worker and 
patient safety, Alberta Health Services (AHS) developed the Hazardous Medication 
Personal Protective Equipment Guide and List (2018b). Prior to the implementation of 
this Guide, health care workers (HCWs) referred to the Cytotoxic Drug Manual 
Administration and Handling Guidelines (AHS, 2013) to identify the required safety 
measures when working with cytotoxic medications. Both the Guide (AHS, 2018b) and 
the Manual (AHS, 2013) provide clinical practice guidance for HCWs caring for adults in 
the community.  
The overall goal for this practicum is to appraise the Hazardous Medication 
Personal Protective Equipment Guide and List (AHS, 2018b) using the Appraisal of 
Guidelines for Research and Evaluation Instrument (AGREE II) (AGREE Trust, 2017). 
92 
 
The purpose of this environmental scan was to create an awareness of available local, 
provincial, and national resources for handling hazardous medications and using Personal 
Protective Equipment (PPE). The findings from this environmental scan will inform the 
appraisal of the Hazardous Medication Personal Protective Equipment Guide and List.  
2. Specific Objective(s) for the Environmental Scan 
 
To identify local, provincial, and national clinical practice guidelines for HCWs 
who are handling hazardous medications in the community. 
3. Sources of Information 
 
 
A google search for “hazardous medications” and “Canada” was conducted. Also, 
a question about the availability of hazardous medication resources (at the local, 
provincial, and national level) was included in the consultations with the Continuing Care 
Workplace Health and Safety Advisor and Continuing Care Hazardous Medication 
Committee Member. Finally, the following websites/online platforms were reviewed to 
identify clinical practice guidelines related to handling hazardous medications in the 
community: 
A) Supportive Living SharePoint: the online platform that houses resources that are 
specific to Supportive Living-Edmonton Zone HCWs.  
B) AHS Insite: the internal website for AHS which houses resources applicable to AHS 
HCWs across the province.   
C) Government of Alberta Occupational Health and Safety (OHS) Online Resource 
Portal: contains OHS legislation and resources relevant to Albertans.  
D) Canadian Centre for Occupational Health and Safety (CCOHS) Website: CCOHS is 
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Canada’s national resource for the advancement of workplace health and safety.   
E) The Canadian Clinical Practice Guideline Infobase: a database of evidence-based 
Canadian clinical practice guidelines maintained by the Canadian Medical Association.  
4. Data Collection 
 
The data for this environmental scan was collected from websites/online platforms 
and by examining the findings of the consultations.  
5. Ethical Considerations 
 
As evidenced by the completion of the Health Research Ethics Authority 
Screening Tool, Research Ethics Board review was not required for this environmental 
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Resource Document Summary 
i) Hazardous Medications Personal Protective Equipment FAQ: This 
document was created by the AHS Hazardous Medication Evaluation 
Committee (HazMEC); a multidisciplinary group that collaborates in the 
development and maintenance of the AHS Hazardous Medication Personal 
Protective Equipment Guide and List to ensure proper and safe handling of 
hazardous medications. The FAQ was written at the provincial level, applies 
to all AHS HCWs, and was developed to complement the Guide and support 
its implementation. The FAQ consists of 54 questions on a number of topics 
including applicability, definitions, disposal, labeling, PPE, medication 
preparation and administration, resources/contacts, spills management, 
storage, and transportation.  
ii) Hazardous Medication Personal Protective Equipment Guide and List 
Tip Sheet: This tip sheet was also developed by the AHS HazMEC and is 
intended to complement the Hazardous Medication Personal Protective 
Equipment Guide and List and support its implementation. This is a concise 
one page document summarizing the purpose of the guide as well as actions 
required by managers/educators and front line HCWs.  
iii) Handling Human Wastes of Patients Receiving Known Hazard 
Medications FAQ: This document was also created by the AHS HazMEC 
and is intended to compliment the Guide by serving as a resource for HCWs 
handling human wastes from patients receiving known hazardous medications. 
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This is a five page FAQ addressing when PPE is required, the length of the 
precautionary period, and waste disposal requirements.  
iv) Cytotoxic Drug Manual Administration and Handling Guidelines: The 
Manual was developed by a working group in the Edmonton Zone which 
consisted of representatives from Nursing, Pharmacy, Workplace Health and 
Safety, and Materials Management. This Manual meets the criteria of a 
clinical practice guideline as it is based on a systematic review of the evidence 
and outlines guidelines for the safe handling and disposal of cytotoxic drugs in 
AHS healthcare facilities and in the homecare setting, in the Edmonton Zone 
(Anaya et al., 2018). The manual was updated in February 2018 to ensure it 
complements the Hazardous Medication Personal Protective Equipment 
Guide and List. It is noteworthy that unlike the Guide, the Manual does not 
endorse the NIOSH list of hazardous medications, it focuses on cytotoxic 
medications only.  
v) Cytotoxic Drug Exposure-OHS Information for Workers and Employers: 
This three page resource is authored by Work Alberta, a division of the 
Government of Alberta. Like the Hazardous Medication Personal Protective 
Equipment Guide and List, this resource defines hazardous medications, 
references the NIOSH hazardous medication list, outlines potential exposures 
and effects, and identifies appropriate PPE. However, this resource is nowhere 
near as comprehensive as the Guide and is not based on a systematic review of 
the evidence. As such, it cannot be considered a clinical practice guideline 
(Anaya et al., 2018).   
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vi) Protection of Workers from Synthetic Opioid Exposure: This seven page 
resource, also authored by Work Alberta, focuses on synthetic opioid 
exposures, the PPE required, and steps for decontamination. Unlike the 
Hazardous Medication Personal Protective Equipment Guide and List, this 
resource emphasizes the fact that healthcare workers may be exposed to 
synthetic opioids unknowingly and outlines the appropriate PPE indications. 
Also unlike the Guide, this resource is not based on a systematic review of the 
evidence and as such cannot be considered a clinical practice guideline (Anaya 
et al., 2018).    
vii) Safe Handling of Hazardous Drugs: This resource is authored by the British 
Columbia Cancer Agency which partners with regional health authorities to 
provide a comprehensive cancer control program for British Columbians. Like 
the Guide, this resource defines hazardous medications, endorses the use of 
the NIOSH hazardous medication list, and provides direction for the safe 
handling of these medications including waste disposal requirements. Given 
the fact that this document is based on a systematic review of the evidence and 
aids in decision making, it is a clinical practice guideline (Anaya et al., 2018).  
viii) Safe Handling of Hazardous Drugs in Healthcare: This resource is 
authored by the Ontario Public Services Health and Safety Association, a 
division of the Ontario Ministry of Labor. Like the Hazardous Medication 
Personal Protective Equipment Guide and List, this document defines 
hazardous drugs, endorses the use of the NIOSH hazardous medication list, 
outlines potential routes of exposure and effects, and provides direction for 
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control measures. While this resource is not nearly as comprehensive as the 
Guide it does meet the criteria of a clinical practice guideline as it is based on 
a systematic review of the evidence and is intended to aid in decision making 
(Anaya et al., 2018).  
ix) NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare 
Settings: Given the fact that this document was referenced in numerous 
Canadian resources about hazardous medications and was mentioned in the 
consultations with the Continuing Care Workplace Health and Safety Advisor 
and Continuing Care HazMEC member, it was included in the environmental 
scan. This document is authored by the NIOSH, the federal OHS agency in the 
United States, and meets the criteria outlined by Anaya et al. (2018) to be 
considered a clinical practice guideline. The hazardous medication list 
contained within this guideline is endorsed in the Hazardous Medication 
Personal Protective Equipment Guide and List and in the documents authored 
by Work Alberta, the British Columbia Cancer Agency, and the Ontario 
Public Services Health and Safety Association cited above. Similar to the 
Hazardous Medication Personal Protective Equipment Guide and List, the 
intent of this guideline is to outline the control measures required to protect 
workers from exposure to hazardous medications. This clinical practice 
guideline is shorter than the Guide (42 pages versus 69) and is less 
prescriptive. That is to say, the NIOSH resource provides general direction for 






The resources found in conducting this environmental scan will be used to 
complete the appraisal of the Hazardous Medication Personal Protective Equipment 
Guide and List. Specifically, the clinical practice guidelines (Cytotoxic Drug Manual 
Administration and Handling Guidelines, Safe Handling of Hazardous Drugs, Safe 
Handling of Hazardous Drugs in Healthcare, and the NIOSH List of Antineoplastic and 
Other Hazardous Drugs in Healthcare Settings) identified at the local, provincial, and 
national level will serve as an important reference point from which to compare the 
Hazardous Medication Personal Protective Equipment Guide and List. This comparison 
will be important in completing the appraisal of the quality of the Guide using the 
AGREE II Framework, specifically as it relates to assessing the Rigor of Development 
domain which takes into consideration the selection of evidence (AGREE Trust, 2017). 
Furthermore, the supporting documents to the Guide identified in completing the 
environmental scan, will be referred to when assigning quality ratings for the critical 
appraisal.  
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Health care workers (HCWs) caring for older adults in the Supportive Living 
setting (SLS) can be at risk for adverse health effects from exposure to hazardous 
medications. Hazardous medications are associated with carcinogenicity, teratogenicity, 
genotoxicity, and reproductive toxicity. To control HCWs’ exposure to hazardous 
medications and enhance worker and patient safety, Alberta Health Services (AHS) 
developed the Hazardous Medication Personal Protective Equipment Guide and List 
(2018), henceforth referred to as the Guide. The Guide applies to all AHS HCWs and 
contracted service providers, including those working in the SLS. Prior to the 
implementation of the Guide, HCWs referred to the Cytotoxic Drug Manual 
Administration and Handling Guidelines (AHS, 2013). The following report summarizes 
the findings from a critical appraisal of the Guide using the Appraisal of Guidelines for 
Research and Evaluation Instrument Version II (AGREE II) guideline appraisal tool. 
The AGREE II Instrument offers a systematic framework for evaluating clinical 
practice guidelines (CPGs) and has been established as a valid and reliable appraisal tool 
(Makarski & Brouwers, 2014). The AGREE II is an appropriate appraisal tool for this 
project because the Guide meets the definition of a CPG and the author qualifies as an 
intended user of the tool (AGREE Trust, 2017). The AGREE II tool has also been used to 
guide the critical appraisal of similar Occupational Health and Safety related CPGs 
(Dewa, Trojanowski, Joosen & Bonato, 2016; Joosen et al., 2015; Shetty, Raaen, 




The AGREE II Appraisal Tool 
 
The AGREE II appraisal tool consists of 23 items that fall under 6 different 
quality domains in addition to two global rating items intended to capture the overall 
quality of a CPG. The first quality domain, Scope and Purpose, addresses the overall 
intent of the CPG, the specific questions it addresses, and the target population. The 
second domain, Stakeholder Involvement, considers whether or not the relevant 
stakeholders were involved in the development of the CPG and if the perspective(s) of the 
intended users are reflected. The third domain, Rigor of Development, evaluates the 
process used to gather and synthesize the evidence, formulate recommendations, and 
update those recommendations. The fourth domain, Clarity of Presentation, pertains to 
the format, structure, and language used in the CPG. The fifth domain, Applicability, 
considers implementation barriers/facilitators as well as the financial implications of 
instating the CPG. The sixth domain, Editorial Independence, addresses whether or not 
the recommendations made in the CPG were unduly biased. Finally, the Overall 
Assessment section includes a rating of the overall quality of the guideline and a rating of 
whether the guideline is recommended for use (AGREE Trust, 2017). 
The Critical Appraisal Process 
 
The AGREE II: User’s Manual (AGREE Trust, 2017) recommends that a 
minimum of two, preferably four appraisers, independently appraise a CPG to support the 
reliability of the assessment. However, for purposes of this practicum project, only the 
author completed the critical appraisal of the Guide. The critical appraisal process began 
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by obtaining a copy of the Guide and carefully reading the entire document to become 
familiar with the contents. All of the supporting documents used in the development of 
the Guide were collected and reviewed as a part of the materials considered in the critical 
appraisal. The author also consulted with a member of the Guide’s development group to 
obtain information about the development of the Guide.  
Data Analysis  
 
The AGREE II Online Guideline Appraisal Tool was used to create the summary 
report on the critical appraisal of the Guide. All of the 23 items on the AGREE II Tool 
were scored on a scale of 1 to 7, with 7 representing the highest rating of quality. 
Frequencies and percentages were analyzed. Item ratings, domain total scores and quality 
score ratings are presented in Table 1.  
There is no research to suggest that specific quality scores are linked to certain 
outcomes (AGREE Trust, 2017), but for purposes of this practicum, a score of 70% was 
considered high quality, between 50 and 69% medium quality, and less than 50% poor 
quality. This high quality threshold score (70%) is in keeping with the literature which 
states that domain quality threshold scores can be set at percentages ranging from 50% to 
70% (Anaya, Franco, Merchan-Galvis, Gallardo & Cosp, 2018; Bragge et al., 2014; Dewa 
et al., 2016; Joosen et al., 2015; MacQueen, Santaguida, Keshavarz, Jaworska, Levine, 





Table 1.  
Domain Total Scores, Items Ratings, and Quality Score Ratings 
















Health Question 7/7 









Target Population 6/7 






























Methods to Formulate 
Recommendations 
5/7 
Benefits, Side Effects, 
and Risks 
6/7 
Links to Evidence 6/7 
External Review 6/7 
















































Findings and Discussion 
 
 The interpretation of the results of this critical appraisal was completed in 
accordance with the AGREE User’s Manual. The User’s Manual offers a number of 
options for approaches to interpreting results. Common to all methods is the requirement 
that domain scores be interpreted independently and not aggregated into a single quality 
score as well as the requirement to compare scores against a pre-set quality threshold. As 
previously mentioned, the pre-set high quality threshold for this appraisal was ≥70%. The 
specific approach to interpretation used for this appraisal is one in which all domains are 
considered to be of equal priority, as opposed to prioritizing one domain over the other or 
assessing for an improvement in scores over time. In this approach, the quality threshold 
is the same across all six domains (AGREE Trust, 2017).  
Scope and Purpose  
With a quality score of 100%, the Scope and Purpose domain received one of the 
highest ratings of quality. This is consistent with other findings reported in the literature 
with Scope and Purpose being the highest scoring domain for CPGs (Anaya et al., 2018; 
Dewa et al., 2016; Joosen et al. , 2015; MacQueen et al., 2017; Mambulu-Chikankheni, 
Eyles, Eboreime & Ditlopo, 2017). Based on this score, it can be concluded that the 





The Guide was scored at 86% for the Stakeholder Involvement domain. This 
indicates that the Guide meets the expectations for involving relevant stakeholders in the 
development process with due consideration having been paid to the perspective(s) of the 
intended users (AGREE Trust, 2017). However, due to the fact that information relevant 
to the members of the development group was not reported in the Guide or supporting 
documents (e.g. names, discipline, relevant expertise, etc.), it is recommended that 
information on the development group be added to future versions of the Guide.     
Rigor of Development  
The Rigor of Development score for the Guide was high at 79%. This high quality 
of rigor in development is reflected in the best practice evidence that was collected and 
used to formulate the recommendations in the Guide. However, unfortunately, the process 
of how the evidence was synthesized and used in the formulation of the recommendations 
was not clearly outlined. Furthermore, this domain score was impacted by the fact that the 
Guide did not outline a process for updating and auditing. As such, it is recommended 
that a process for updating and auditing the content be included in future versions of the 
Guide.    
Clarity of Presentation  
The quality score calculated for the Clarity of Presentation domain was 100%, 
indicating that the different options for the prevention of the health issue for SL HCWs’ 
occupational exposure to hazardous medications were clearly outlined in the document. It 
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also indicates that the options presented are tailored to the specific workers and clinical 
situations involved. This high score is reflective of a pattern of high scores for CPGs in 
the Clarity of Presentation domain, as shown in the literature (Dewa et al., 2016; 
MacQueen et al., 2017; Mambulu-Chikankheni et al., 2017; Shetty et al., 2018).  
Applicability  
   The Applicability domain was scored at 68%, which reflects medium quality. This 
score indicates that implementation barriers and/or facilitators may not have been fully 
considered by the developers (AGREE Trust, 2017). Interestingly, patterns identified in 
the literature indicate that CPGs consistently score low on the Applicability domain 
(Anaya et al., 2018; Bragge et al., 2014; Dewa et al., 2016; MacQueen et al., 2017). The 
quality score for this domain is less than the pre-set threshold, partly due to the fact that 
there are no supporting documents to address the resource implications of implementing 
the recommendations. Specifically, the costs of the PPE, spill kits, waste management 
equipment, and waste management processing, as well as who is responsible for paying 
for these costs, are not discussed. Secondly, no monitoring or auditing criteria are 
provided to evaluate the implementation of the Guide. As such, these findings informed 
the development of recommendations to clearly identify the required resources for 






Editorial Independence  
The domain score for Editorial Independence for the Guide was 21%, which was 
well below the pre-set threshold. The low rating for this item is based on the fact that 
there is no explicit statement acknowledging that the views or interests of the funding 
body have not influenced the content of the Guide and that group members have no 
conflict of interest in developing the Guide. Despite these omissions, it is clear that the 
content of the Guide is based on best practice evidence and not personal opinions.  
This low score for the Editorial Independence domain is consistent with patterns 
from the literature in which other CPGs also received sub-threshold quality scores 
(Bragge et al., 2014; Joosen et al., 2015; Mambulu-Chikankheni et al., 2017). With such a 
low quality rating, one cannot be certain that the recommendations made in the Guide are 
not unduly biased (AGREE Trust, 2017). Therefore, it is recommended that the funding 
body and the group developing the Guide, explicitly state whether or not there are any 
conflict(s) of interest and that the content of the Guide was not influenced by personal 
views or opinions.  
Overall Quality  
The overall quality for the Guide was rated a 5 out of 7, which translates to a score 
of 71% thus indicating that the Guide is a high quality document. Furthermore, the Guide 





Limitations of the Critical Appraisal 
 There are three identified limitations of note with respect to this critical appraisal 
process. Firstly, only one appraisal was conducted while the User’s Manual recommends 
that at least two and ideally four be conducted to support the reliability of the assessment 
(AGREE Trust, 2017). Secondly, the AGREE II is intended to be used to evaluate the 
methodological quality of CPG development, not the clinical appropriateness or validity 
of the recommendations within it (Anaya et al., 2018; Bragge et al., 2014; Joosen et al., 
2015; MacQueen et al., 2017). As such, the results of this appraisal cannot confirm nor 
disaffirm the clinical appropriateness or the efficacy of the recommendations within the 
Guide. An evaluation of the efficacy of the recommendations to prevent occupational 
exposures to hazardous medications would require the application of a framework 
designed to assess the quality of evidence such as the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) Method (Besselaar et al., 2017; 
MacQueen et al., 2017).  
A third limitation of note is that the AGREE II Tool does not comprehensively 
appraise the implementability of CPGs (Makarski & Brouwers, 2014). While the 
Applicability domain contains a number of items related to implementability, such as 
barriers and facilitators to implementation as well as resource implications, developers of 
the AGREE II acknowledge the need for a more comprehensive assessment of 
implementability (Makarski & Brouwers, 2014). In fact, it is this limitation that inspired 
the development of the AGREE-Recommendation Excellence (REX), a complementary 
tool to the AGREE II, intended to be used to conduct a comprehensive evaluation of a 
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guideline’s clinical credibility and implementability (AGREE Enterprise, 2018). 
Unfortunately, this tool is still under development and not available for use at this time. It 
is acknowledged that the critical appraisal process completed for this report did not 
involve a comprehensive assessment of the implementability of the Guide. 
Summary of Recommendations 
1. Two to four appraisers use the AGREE II to appraise the Guide. 
2. Add a section with the names, disciplines, relevant expertise, institution, 
geographic location, and the role of each member who was involved in the 
development of the Guide.  
3. Describe the development process including the methodology used to conduct the 
external review, the strategy used to search for and select the evidence, and a 
description of the strengths and limitations of the evidence.  
4. Develop a procedure for updating the contents of the Guide.  
5. Identify the costs of PPE, spill kits, waste management equipment, and waste 
management processing as well as who is responsible for those costs.  
6. Develop monitoring and/or auditing criteria to conduct an evaluation of the 
implementation of the Guide (e.g. hazardous medications are correctly identified 
and labeled by pharmacy, hazardous medications are identified and communicated 
as being hazardous amongst the facility HCWs, the correct PPE is being used, 
waste management requirements are being followed, and site specific hazardous 
medication management processes are followed).  
114 
 
7. Include a statement explicitly stating the role of the funding body in the 
development of the Guide.  
8. Include a statement explicitly declaring the presence or absence of any conflicts of 
interest on behalf of the guideline development group members.  
Conclusions 
 
The critical appraisal of the Hazardous Medication Personal Protective 
Equipment Guide and List (AHS, 2018) using the ARGEE II Tool showed that the Guide 
is a high quality CPG that could provide expert guidance for HCWs in the SLS. However, 
there is room to improve the quality of the Guide, especially in the Applicability and 
Editorial Independence domains. Recommendations for improvement include outlining 
the resource implications of instating the Guide, developing monitoring and/or auditing 
criteria to evaluate its implementation, and including a statement indicating the views of 
the funding body and the interests of the guideline development group members. While 
the critical appraisal findings suggest that the methodological quality of the development 
of the Guide is high, further work is needed to comprehensively evaluate the clinical 
appropriateness and implementability of the guideline. In conclusion, based on the results 
of this critical analysis, the Guide is recommended for use to help control HCWs’ 
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Overall Assessment  
Title: Hazardous Medication Personal Protective Equipment Guide and List  
Overall quality of this guideline: 5/7  
Guideline recommended for use? Yes with modifications.  
Notes: 
Recommended modifications: 1) include the name, disciplines, relevant expertise, 
institution, geographic location, and the role in development of each member of the 
guideline development group, 2) include a section outlining the guideline development 
process that was used including: the methodology used to conduct the external review, the 
strategy used to search for and select the evidence, and a description of the strengths and 
limitations of the evidence, 3) include a procedure for updating the Guide and supporting 
documents, 4) include a section that addresses the resource implications of implementing 
the recommendations including the costs of PPE, spill kits, waste management 
equipment, and waste management processing as well as who is responsible for paying 
for same, 5) include monitoring and/or auditing criteria for the Guide, and 6) include a 
statement addressing if and how the funding body influenced the final recommendations 
as well as a statement declaring the presence or absence of competing interests for the 
development group members.  
Domain Total 
1. Scope and Purpose 21 
2. Stakeholder Involvement 18 
3. Rigor of Development 44 
4. Clarity of Presentation 21 
5. Applicability 19 
6. Editorial Independence 3 
 
1. Scope and Purpose  
1. The overall objective(s) of the guideline is (are) specifically described.  
Rating: 7  
The overall objective of the guideline is specifically described in the Preamble section: 
“to provide guidance for safe handling of hazardous medications in Alberta Health 
Services (AHS) and Covenant Health (CH) and to reduce occupational exposure to 




2. The health question(s) covered by the guideline is (are) specifically described.  
Rating: 7  
A detailed description of the health questions covered by the guideline are specifically 
described. Key questions include: 1) What is a hazardous medication?, 2) What 
medications are hazardous?, 3) What is an occupational exposure?, 4) Who does this 
apply to?, and 5) How are occupational exposures to hazardous medications prevented or 
reduced? The key health questions covered by the Guide are listed individually in the 
table of contents which allows the user to easily access the required information. By 
answering each of the key questions, the authors indicate the target population, the 
potential exposures, the required interventions, and the intended outcomes of the Guide.  
3. The population (patients, public, etc.) to whom the guideline is meant to apply is 
specifically described.  
Rating: 7  
The population to whom the guideline is meant to apply is described in the Guide. The 
Preamble addresses who the Guide applies to; “all AHS and CH employees, members of 
the medical and midwifery HCWs, students, volunteers, and other persons acting on 
behalf of AHS or CH (including contracted service providers as necessary) (AHS, 2018b, 
p. ii). Unfortunately, there is no rationale provided within the Guide itself explaining 
exactly when it is necessary for contracted service providers to follow it. However, in the 
Hazardous Medication PPE Guide Frequently Asked Questions supporting document this 
is addressed under the question heading: “I am a contracted service provider, do I need to 
follow this Guide?” In this section of the Hazardous Medication PPE Guide Frequently 
Asked Questions document it is explained that contracted service providers are strongly 
encouraged to follow the Guide and use it as a resource for the development of their own 
policies and procedures. Additionally, under the Who Does This Apply To section, 
specific departments, including specific roles within those departments, to which the 
Guide applies are listed. Also, in the Reproductive Hazard Medication in AHS/CH 
section, the Guide defines the specific HCWs population to whom hazardous medications 
from the reproductive category pose a hazard: “men or women with a potential to 
conceive, women who are pregnant, or women who are breast feeding” (AHS, 2018b, 
p.6). 
2. Stakeholder Involvement  
4. The guideline development group includes individuals from all relevant 
professional groups.  
Rating: 6  
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The guideline development group consisted of the AHS Hazardous Medication 
Evaluation Committee, the AHS Hazardous Medication Evaluation Panel, AHS 
Pharmacy Services Medication Quality and Safety Team, AHS Health Professions 
Strategy and Practice, AHS Pharmacy Services Technical Practice Leads, AHS Human 
Factors, AHS Workplace Health and Safety, and the CH Medication Management and 
Safety Team. However, neither the Guide, nor the supporting documents, indicate the 
name, discipline, relevant expertise, institution, geographical location, and role in 
development of each member of the guideline development group. However, the 
Hazardous Medication PPE Guide Frequently Asked Questions document does indicate 
that the development group consisted of a physician, pharmacists, and nurses.  
5. The views and preferences of the target population (patients, public, etc.) have 
been sought.  
Rating: 6  
The Guide itself does not outline the development process that was used, or more 
specifically, the strategy used to capture workers’ views and preferences. However, based 
on the fact that a number of AHS and CH committees, which consist of AHS and CH 
employees, were identified in the Guide as it’s developers, it can be confirmed that at 
least some members of the target population participated in the development of the Guide. 
Furthermore, a consultation with a guideline development group member revealed that 
feedback was sought from members of the target population with revisions made to the 
documents based on same.  
6. The target users of the guideline are clearly defined.  
Rating: 6  
The target users of the guideline are defined in the Preamble and in the Who Does This 
Apply To sections of the Guide. The Who Does This Apply To section is listed in the 
table of contents which allows users to readily access this information. However, as 
previously mentioned in the scoring for item #3, the Guide itself does not explain when it 
is “necessary” for contracted services providers to follow it. That being said, the 
Hazardous Medication PPE Guide Frequently Asked Questions supporting document 
provides clarity by advising that contracted service providers are strongly encouraged to 








3. Rigour of Development  
7. Systematic methods were used to search for evidence.  
Rating: 6  
While there is no description of the strategy used to search for evidence there is a note in 
the Resources and References section indicating that information contained within the 
Guide came from 15 difference sources, for which references are provided. Furthermore, 
consultation with a member of the guideline development group revealed that a 
comprehensive literature review on the subject matter was completed as a part of the 
development process.  
8. The criteria for selecting the evidence are clearly described.  
Rating: 7 
There are numerous references to the National Institute of Occupational Safety and 
Health (NIOSH) list of hazardous medications and the NIOSH Preventing Occupational 
Exposures to Antineoplastics and Other Hazardous Drugs in Health Care Settings clinical 
practice guideline in the Guide. Although there is no report in the Guide or supporting 
documents as to the criteria that was used to select this evidence, the NIOSH organization 
is an international leader in the Occupational Health and Safety field and as such 
references to their resources are very appropriate.  
9. The strengths and limitations of the body of evidence are clearly described.  
Rating: 6  
Although there is no description of the strengths and limitations of the body of evidence 
provided in the Guide or other supporting documents, the process by which the Guide 
was developed (as reported by a member of the guideline development group) as well as 
the references contained within it suggest that considerations of same were made.  
10. The methods for formulating the recommendations are clearly described.  
Rating: 5  
While references to credible information sources are included, there is no description of 
the methods used to formulate the recommendations within the Guide itself. However, in 
the Hazardous Medication PPE Guide Frequently Asked Questions supporting document 
there is a brief rationale provided as to how hazard levels were assigned for hazardous 
medications under the question heading: “How did AHS assign hazard levels for 
hazardous medications?” The answer provided is that decisions were “based 
predominantly on NIOSH decisions (when known), application of NIOSH criteria when a 
NIOSH decision was not known, or evaluation of available data when necessary” (AHS, 
2018c, p. 7).  
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11. The health benefits, side effects, and risks have been considered in formulating 
the recommendations.  
Rating: 6  
There is evidence that the risks associated with occupational exposures to hazardous 
medications were considered in the development of the recommendations. The 
recommendations made within the Guide are accompanied with references to supporting 
data which highlight these risks.  
12. There is an explicit link between the recommendations and the supporting 
evidence.  
Rating: 6  
There is a link between the recommendations made within the Guide and the supporting 
evidence as demonstrated by the references made to information sources. However, not 
every recommendation made within the Guide is accompanied by an explicit link to the 
evidence. 
13. The guideline has been externally reviewed by experts prior to its publication.  
Rating: 6  
Although the methodology used to conduct an external review was not reported on within 
the Guide or supporting documents, a consultation with a guideline development group 
member revealed that the guideline was reviewed externally before it was approved and 
implemented. The Guide was distributed to leadership and frontline AHS HCWs as well 
as to contracted service providers for feedback. Revisions were made to the Guide and the 
supporting documents based on this feedback. Furthermore, the common questions posed 
by these external reviewers were collated into a Frequently Asked Questions resource 
document intended to support the use of the Guide.  
14. A procedure for updating the guideline is provided.  
Rating: 2  
No procedure for updating the guideline is outlined in the Guide or supporting 
documents. The only mention of updates is made in the Hazardous Medication List-Key 
Points section of the Guide where it is stated that “The Hazardous Medication List will be 
reviewed and updated on a periodic basis as new medication or information becomes 






4. Clarity of Presentation  
15. The recommendations are specific and unambiguous.  
Rating: 7  
The recommendations contained within the Guide are specific and unambiguous. Based 
on the user’s role and the type of Hazardous Medication (known, potential, or 
reproductive), the user looks up the task they will be performing to identify the specific 
PPE that is required (e.g. 2 pairs of gloves, a DMR Chemo gown, a N95 mask, etc.). 
Caveats are included in the recommendations to provide clarification where appropriate. 
For example, for medications posing a reproductive hazard, a description of the specific 
population at risk is provided.  
16. The different options for management of the condition or health issue are clearly 
presented.  
Rating: 7  
This item was scored as a 7 because the Guide clearly presents recommendations for the 
prevention of the health issue (i.e. occupational exposure to hazardous medications). 
Furthermore, the recommendations made in the Guide are tailored to the specific worker 
and clinical situation involved. 
17. Key recommendations are easily identifiable.  
Rating: 7  
Despite the fact that the Guide is dense with information, recommendations are easily 
identifiable. Recommendations are easy to identify because of the clear and logical 
organization of the Guide, the presentation of recommendations in chart format which 
includes pictures, and the existence of the Hazardous Medications Handling Risk 
Assessment Algorithm (AHS, 2018b, p. 61) which directs the user how to use the Guide. 
5. Applicability  
18. The guideline describes facilitators and barriers to its application.  
Rating: 6  
Some of the barriers to the application of the Guide are addressed within the Guide itself. 
For example, in the Preamble the Guide acknowledges that it may not cover all possible 
situations but advises that when the user is in doubt to assume precautions to protect 
themselves from occupational exposure to hazardous medications. Another barrier 
addressed in the Guide is that different sites use different waste disposal containers. 
However, examples are provided in the Guide of the most commonly used containers and 
it outlines which ones are preferred and which ones are acceptable for use if a preferred 
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container is not available. On the other hand, a number of barriers to implementation are 
not addressed within the Guide itself such as how to access the preferred waste 
containers. Fortunately, many of these barriers are addressed in the supporting documents 
which include the Hazardous Medication PPE Guide Frequently Asked Questions 
document (AHS, 2018c) and the Handling Human Waste of Patients Receiving Known 
Hazard Medications Frequently Asked Questions document (AHS, 2018a).  
19. The guideline provides advice and/or tools on how the recommendations can be 
put into practice.  
Rating: 6  
The Guide provides tools on how the recommendations can be put into practice. These 
tools include the Hazardous Medication PPE Guide Frequently Asked Questions 
document (AHS, 2018c), Handling Human Waste of Patients Receiving Known Hazard 
Medications Frequently Asked Questions document (AHS, 2018a), the Hazardous 
Medication PPE Guide Tip Sheet (AHS, 2018d), and the Safe Handling of Hazardous 
Medication Guiding Practice (AHS, 2018e). These tools are referenced within the Guide 
itself and are also available on the AHS Hazardous Medication landing page on Insite. 
However, no information is provided in any of the aforementioned documents as to the 
development and validation procedures used for these tools.  
20. The potential resource implications of applying the recommendations have been 
considered.  
Rating: 6 
There is evidence that the potential resource implications of implementing the 
recommendations in the Guide were considered. Although not identified in the Guide 
itself, the Hazardous Medication PPE Guide Frequently Asked Questions document 
(AHS, 2018c) addresses the teaching resources that are available to support the 
employers\' education of their employees regarding hazardous medication management. 
However, the documents do not address what the costs of the PPE, spill kits, waste 
management equipment, and waste management processing are or who is responsible for 
paying for them.  
21. The guideline presents monitoring and/or auditing criteria.  
Rating: 1  
There is no monitoring and/or auditing criteria identified in the Guide or supporting 
documents. No strategies for the evaluation of the guideline or associated quality or audit 




6. Editorial Independence  
22. The views of the funding body have not influenced the content of the guideline.  
Rating: 2  
While the funding body for the Guide is identified, there is no explicit statement 
acknowledging that the views or interests of AHS and CH have not influenced the final 
recommendations.  
23. Competing interests of guideline development group members have been 
recorded and addressed.  
Rating: 1  
Neither the Guide, nor its supporting documents, contain an explicit statement that all 
group members have declared whether or not they have any competing interests. 
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